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Abstract
AN APPLIED MATHEMATICS APPROACH TO MODELING
INFLAMMATION: HEMATOPOIETIC BONE MARROW STEM CELLS,
SYSTEMIC ESTROGEN AND WOUND HEALING AND GAS EXCHANGE IN
THE LUNGS AND BODY
By Racheal L Cooper
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016.
Director: Dr. Angela Reynolds,
Associate Professor, Department of Mathematics and Applied Mathematics
Mathematical models apply to a multitude physiological processes and are used
to make predictions and analyze outcomes of these processes. Specifically, in the
medical field, a mathematical model uses a set of initial conditions that represents
a physiological state as input and a set of parameter values are used to describe
the interaction between variables being modeled. These models are used to analyze
possible outcomes, and assist physicians in choosing the most appropriate treatment
options for a particular situation. We aim to use mathematical modeling to analyze
the dynamics of processes involved in the inflammatory process.
First, we create a model of hematopoiesis, the processes of creating new blood
cells. We analyze stem cell collection regimens and statistically sample parameter
space in order to create a model accounts for the dynamics of multiple patients. Next,
we modify an existing model of the wound healing response by introducing a variable
xi
for two inflammatory cell types. We analyze the timing of the inflammatory response
and introduce the presence of systemic estrogen in the model, as there is evidence that
the presence of estrogen leads to a more efficient wound healing response. Last, we
mathematically model the gas exchange process in the lungs and body in order to lay
the foundation for a model of the inflammatory response in the lung under conditions
of mechanical ventilation. We introduce normal and ventilation breathing waveforms
and a third state of hemoglobin in a closed loop partial differential equations model.
We account for gas exchange in the lung and body compartments in addition to
introducing a third discretized well-mixing compartment between the two.
We use ordinary and partial differential equations to model these systems over
one or more independent variables, as well as classical analysis techniques and compu-
tational methods to analyze systems. Statistical sampling is also used to investigate
parameter values in order for the mathematical models developed to account for
patient-to-patient variability. This alters the traditional mathematical model, which
yields a single set of parameter values that represent one instance of the physiology,




Mathematical models of physiological processes are useful tools that can aid physi-
cians in making decisions about patient care. The in depth design and analysis of
these models in necessary in order to ensure that these models can be used effectively.
In this thesis, we develop several mathematical models that describe various stages
of the inflammatory response and various biological systems in which inflammation
is present. While the inflammatory response is necessary to prevent infection and
disease, an impaired inflammatory response can lead to the presence of chronic in-
flammation and can lead to problems in basic processes required for survival. For
example, an emergent trauma patients’ natural immune response oftentimes culmi-
nates into an impaired immune response that delays the deposition of collagen, an
essential part of the wound healing process, which can lead to a life threatening septic
situation and exacerbate the original trauma. Also, the presence of inflammation in
lung capillaries can cause the swelling of the tissue barrier that decreases the oxy-
genation of blood in the lung capillary or even completely causes oxygenation to be
impossible. Therefore, damage caused by this natural immune response can accumu-
late over multiple lung breath cycles and lead to improper oxygenation of the body
tissue. On the other hand, the presence of systemic mediator estrogen in the wound
healing processes modulates the influx of immune cell populations in such a way that
wound healing may occur more efficiently. There are many driving factors in success-
ful inflammatory response, and so the mathematical modeling of these processes can
aid physicians in making choices that could benefit patient care.
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We begin by developing an ordinary differential equations model of the origin of
blood cells: erythrocytes, white blood cells, and thrombocytes/platelets. These cell
types originate in the bone marrow as hematopoietic stem cells, which differentiate
into committed progenitor cells that proliferate and differentiate into mature progen-
itors in the bone marrow (BM). From the bone marrow, these mature progenitors
move out into the peripheral blood (PB) where erythrocytes are responsible for oxy-
genating body tissue and white blood cells and platelets function in wound healing
and the inflammatory processes [1]. In addition to the presence of these blood cell
types in the PB, stem cells also move from the BM into the PB where they lie dormant
in the cycling PB and populate stem cell pools in other parts of the body, such as the
spleen. The function of cells involved in this process are adversely affected in cancers
of the blood [2, 3, 4]. Specifically, we will focus on lymphoma which is marked by the
presence of increased amount of lymphocytes in the PB and accumulation of lympho-
cytes in the lymph nodes [3]. The treatment of patients with lymphoma involves a
combination of chemotherapy and radiation followed by transplantation of PB stem
cells collected prior [5, 6]. Drug treatments are used during the collection process,
which occurs before chemotherapy and radiation, to facilitate the movement of stem
cells into the PB, in addition to other dynamics. Following drug treatment, stem
cells are collected from patients that will be used later for transplantation in order to
repopulate the bone marrow stem cells [6]. Oftentimes, this collection is unsuccessful,
i.e. not enough cells are obtained from the collection process, and the resulting stem
cell population is not adequate to repopulate the patient’s bone marrow stem cells
following chemotherapy treatment. If this is the case, the patient undergoes a second
drug treatment regimen and subsequent collection process. Physicians primarily only
use this second drug in poor mobilizaton circumstances due to its substantial cost [7,
8]. A mathematical model of this process could prove useful in determining which
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patients would benefit from using the second drug despite the cost and reduce the
time between diagnosis and treatment of disease.
Next, we modify an existing ordinary differential equations model of inflamma-
tion and subsequent collagen deposition in the wound healing process. We begin by
introducing two variables that represent neutrophils and macrophages individually.
Specifically, these cell populations have different influx dynamics and are activated
by different cell types in the wound. This modification is essential in that it allows
for the inclusion of the systemic mediator estrogen, which is known to affect the two
populations differently [9, 10, 11]. We validate this model using simulations with
the removal of each inflammatory cell population. We then use the model to explore
how the removal of estrogen from the system alters the wound healing process. Orig-
inally, the model was created based on dynamics of female mice where estrogen is
present. The modification of the parameter values accounts for the lack of estrogen
and validates the model based on the change in neutrophil levels when estrogen is
present. Similar to the previous model, we also sample parameter space in order to
create a population of patients that have estrogen present and estrogen absent. This
model is designed to be used by physicians to study the presence of system estrogen
in modulating the wound healing response in such a way that the outcomes of healing
are more effective.
Last, we modify an existing partial differential equations model of blood flow and
gas exchange in the lung capillary to account for a more accurate airflow waveform
in the airspace for normal breathing and mechanical ventilation breathing. It is
common for hospital patients to require the use of mechanical ventilation, which is
known to be potential harmful to the lung if too much air is forced into the lung during
inhalation. If this occurs, the individual alveolus in the lung can be stretched to a
point where the damages causes inflammation to enter into the capillary and cause
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the alveolus to shunt and not be involved in the breathing process. Accumulation of
damage because of this can be detrimental to the patient [12]. In order to do this, we
introduce multi-state hemoglobin dynamics into the existing mathematical model [13].
An unsaturated state of hemoglobin is introduced to create a model that accounts
from three states of hemoglobin dynamics: nonoxygenated, partially oxygenated, and
fully saturated). This modification will create a model that allows for the inclusion of
a non-oxygenated hemoglobin state, and thus a better mathematical representation
of the adverse effects of an impaired inflammatory response in the lung.
In addition to this, we create a 200 spacial unit model of gas exchange in the body.
We account for oxygen loss from the blood to the tissue and the uptake of carbon
dioxide from the tissue into the blood. After the blood flows through the body, it
exits the body compartment in a low oxygen state and feeds directly into a 20 spacial
unit lung compartment, where the carbon dioxide is lost to the airspace and more
oxygen is gathered to be dispersed through the body. When the oxygenated blood
leaves the lung, it feeds into a well mixing compartment which allows for the mixing
of oxygen that comes from different parts of the lung. Once mixed, the oxygen-rich
blood enter back into the body and the process continues. Last, we include a model
of pH in the blood of the lungs and body that can be included in the full model
to account for the presence of carbon dioxide in the bicarbonate buffer system, the
main driver of pH regulation in the body. The presence of carbon dioxide affects the
hemoglobin saturation rate in the blood, and therefore the inclusion of these dynamics
in the model are important to the overall model of gas exchange in the capillaries of
the lung [14]. This mathematical model can be used to analyze the accumulation of
damage due to inflammation in the mechanical ventilation situation and/or the effect
of the presence of inflammation in the lung in disease states such as COPD.
We use mathematical modeling techniques common used in applied mathematics
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and mathematical biology to analyze and learn more about physiological systems and
processes that would otherwise require expensive studies and cause harm to patients.
We use classical numerical analysis techniques to analyze the systems and Latin-
Hypercube Sampling (LHS) techniques to sample parameter space of biologically-
signifiant parameters. We sample the parameter space uniformly and we choose
relevant ranges on the parameter values, and after a set is selected, we analyze the
outcome to ensure biologically relevant dynamics. If the outcome of the simulation of
the parameter set is desirable, it is accepted as a possible set to represents a patient.
In the future, the work could be used to study and analyze specific possible outcomes
based on information obtained about individual patients. If this can be successfully
achieved, these models can then be used to predict whether or not patients will
respond to treatment or need expensive intervention early on and thus shorten the
time between patient admittance and diagnosis and treatment.
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CHAPTER 2
MATHEMATICAL MODEL OF BONE MARROW AND
PERIPHERAL BLOOD STEM CELLS
2.1 Introduction
Hematopoietic malignancies such as leukemia, multiple myeloma, and lymphoma
are treated using combinations of chemotherapy, radiation, and hematopoietic stem
cell transplantation [3, 4, 2]. These cancers often recur after treatment causing pa-
tients to require multiple treatments [15]. Therapy for relapsed hematological malig-
nancies often involves collection of functional hematopoietic stem cells (HSC) in order
for transplantation after marrow-ablative chemotherapy and radiation have been ad-
ministered [16]. In this paper, we mathematically model mobilization and collection
of HSCs with commonly used stem cell mobilizing agents in order to aid physicians
in the treatment of cancers of the blood.
The hematopoietic stem cell population distributed throughout the bone marrow
(BM) is responsible for maintaining normal levels of terminally differentiated cell
populations, such as erythrocytes, leukocytes, lymphocytes and platelets [17, 18, 19,
2]. HSCs that differentiate into the committed hematopoietic progenitors undergo
maturation to become the various cell populations circulating in the blood. Within
the bone marrow niche, cell types such as osteoblasts, osteoclasts, and other stromal
cell populations support HSCs. After differentiation, the matured cells migrate out
of the bone marrow into peripheral circulation [20].
Lineage-specific growth factors influence the differentiation of HSCs into differ-
entiated cell types. For example, erythropoietin levels increase when oxygen levels
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in the body decrease, which is a specific signal for erythrocyte progenitor cells and
increases erythrocyte levels [2, 21]. Similarly, thrombopoietin regulates the produc-
tion of platelets, and monocyte colony-stimulating factor and granulocyte-monocyte
colony-stimulating factor regulates the production of monocytes. Granulocyte colony-
stimulating factor (G-CSF) regulates the production of neutrophils [2, 21, 22, 4]. G-
CSF also stimulates the migration of CD34+ HSC into the peripheral circulation [23,
24]. Cell surface expression of CD34+ indicates a population of cells that contain
true repopulating HSC is the primary indicator of the numbers HSCs present [18, 21,
25].
We will focus on the mechanisms of the maintenance of red blood cells, white
blood cells, platelets, and circulating CD34+ cells, also referred to as peripheral blood
stem cells (PSC), under normal homeostatic conditions. We will also analyze CD34+
stem cell mobilization, collection, and transplantation in normal patients, and dis-
eased patents under drug treatments. To do this, we must account for two different
progenitor cell types in addition to the populations of stem cells in the BM, which is
required to accurately capture homeostatic concentrations of these cell types in the
peripheral blood. In addition, we study the mobilization process in the presence of
Filgrastim, recombinant G-CSF, and its use in combination with Plerixafor, a CXCR4
antagonist with stem cell mobilizing properties commonly used in patients that are
resistant to Filgrastim. Autologous stem cell transplantation (ASCT), where patients
with lymphoma donate stem cells for themselves, is a common form of transplanta-
tion, and will be the focus of our mathematical modeling of stem cell mobilization
in patients. ASCT is used for patients with hematological malignancies such as lym-
phoma and multiple myeloma [3, 16, 26].
Patients that undergo ASCT are first given Filgrastim, which increases the pro-
liferation and differentiation of HSCs within the bone marrow, and mobilization of
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HSCs into the peripheral blood (PB) [27]. In a process called apheresis, PSCs are col-
lected ex vivo, a process taking up to six hours per day and can be carried out for up
to four days until the target number of PSC is collected [28, 29, 30]. Patients whose
stem cell mobilization and collection yield around 5 million CD34+ cells/kg (around
430 million total CD34+ cells) are considered successful collectors and are eligible for
transplantation following chemotherapy and radiation treatments. If the total cell
counts are not high enough, the donor is often treated with Plerixafor to enhance
the mobilization of HSCs to reach the targeted collection goal [31, 32, 33]. Plerixafor
is expensive so it is not used in patients unless Filgrastim-mediated collection is not
successful.
In this paper, we will develop a mathematical model to study the dynamics of
hematopoietic cell population growth and differentiation [34, 35] and how the two
drugs discussed effect mobilization [36, 37, 38]. There exist several mathematical
models of the dynamics in the HSC system in conjunction with GCS-F kinetics in
humans, but none with the dynamics of Filgrastim used in conjunction with Pler-
ixafor. One model, developed by Tibken and Hofer (1996), accounts for stem cells
numbers and relative changes during radiation treatment of leukemia. The model
uses patient data but considers cell numbers after transplantation and does not take
drug treatments into consideration [39]. A model developed by Steinbach et al. con-
siders granulopoiesis with BM maturation and reserve pools of stem cells in canines
[40]. Both consider perturbations of cell types in the system and how this may effect
granylopoiesis.
A series of articles [41, 42, 21] discuss a compartmental model of hematopoiesis
that accounts for differentiation of HSCs into erythrocytes, neutrophils, and platelets.
This model uses time delay terms to account for the proliferation phase of the cell
types mentioned. These articles discuss the presence and importance of oscillations
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in the system and model the effect of treatment with Filgrastim using simulations.
The results are compared to data in patients with lymphoma. In addition to this
model, numerous other models exist that focus on the levels of neutrophils following
Filgrastim treatment and focus on the presence of neutropenia developing during the
treatment process [43]. Our model aims to account for dynamics of the growth and
differentiation of the three major circulating cell populations and how they react to
drug levels and the collection process without time delay differential equations and
to account for various in this response within a population of patients.
We aim to create a model to account for the stem cell mobilization process
by instead accounting for two different types of bone marrow progenitors: commit-
ted progenitors that result from HSCs and those that are committed to becoming a
specific type of functional blood cells, described in the following section. These com-
mitted progenitors then mature in the BM before migrating to the PB compartment
and function as per their cell type. First, we account for this process in a normal per-
son, someone who would not normally require transplantation and fit to data from
normal individuals that donated their stem cells. Then, we sample the parameter
space, using the normal person’s parameter set as a starting point, in order to model
patients with lymphoma. We accept resulting parameter sets based on the change
in dynamics that is biologically relevant to the disease state and we simulate drug
treatment, resulting mobilization, and subsequent collection of each of these patients.
The resulting collection can then be classified as either successful or unsuccessful
collectors. Sampling is then used to evaluate varying responses to Filgrastim and
treatment of poor collectors with Plerixafor is simulated.
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2.2 Model Development
2.2.1 Normal State Model
To model the process of hematopoiesis, we develop a system of ordinary differ-
ential equations that account for the interaction of cells within both the BM and PB
compartments. In the BM compartment we model CD34 +HSCs (C), the committed
platelet/thrombocyte (Lc), erythrocyte (Rc), and leukocyte (Nc) lines, and fully dif-
ferentiated cells for each cell line (Lp, Rp, and Np, respectively). In the PB, we model
the blood components of these lines (Lb, Rb, and Nb, respectively) and the CD34+
cells that arise from the BM (P ). The schematic in Figure 1 shows the components of
the hematopoiesis process included in this model. Several cell types that are known
to be present within the BM are omitted from the model, such as lymphocytes and fat
cells, in order to capture the dynamics of the cell lines that function in hematopoiesis.
HSC dynamics are modeled by Equation (2.1). Their proliferation is modeled by
the first term scC
1+(R+L+N)/c∞
. The denominator inhibits the proliferation rate sc by the
amount of cells in the blood (the sum of Rb, Nb, and Lb), where c∞ controls the ability
of these cells to modulate this proliferation. The second term, −(kcrc + kclc + kcnc)C,
accounts for the differentiation of HSCs into subsequent committed cells, erythrocytes,
lymphocytes, and neutrophils, respectively at rates kcxc, and is negative to indicate a
loss of HSCs when committed cells differentiate into precursor cells. The third term,
kcp
vm
(P − C), accounts for the movement of BM stem cells into the PB at rate kcp,
where vm is the relative size of the BM compartment. Division by vm scales the rates
of differentiation to account for the relative change in concentration due to the cells
moving between compartments. A diffusion type term is used here in order to capture
the ability of the stem cells in the PB to repopulate the HSCs. The last term, −µcC,
10
Fig. 1. Model schematic outlining the progression of cell populations in the BM and PB
compartments. In the BM compartment, the solid line indicates proliferation and
short-dashed line indicates differentiation. The long-dashed line indicates movement
from the BM into the PB that occurs in both directions. The red lines with bars
indicate the inhibitory effect of blood cells on their progenitors in the bone marrow.
A single star indicates interactions with processes that are effected by Filgrastim
and a double star indicates interactions that are effected by both Filgrastim and
Plerixafor.
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1 + (Rb +Nb + Lb)/c∞
− (kcrc + kclc + kcnc)C +
kcp
vm
(P − C)− µcC (2.1)
The equations that model the remainder of cell populations in the bone mar-
row have similar forms, since all cells progress through similar dynamics, committed
cells in the bone marrow (Rc, Nc, and Lc) to terminally differentiated erythrocytes,
white blood cells, and platelets (Rm, Nm, and Lm, respectively). The terminally
differentiated cells can then move out of the BM and into the PB. They each have
uni-directional movement through and out of the bone marrow. Committed cells, dif-
fer from progenitor cells in that they proliferate, first term of Equations (2.2)-(2.4).
The source rate is modulated by the peripheral blood, similar to the first term in the
HSC equation. However, instead of being modulated by the size of the entire blood
compartment, it is modulated only by the cell population in the PB down the line
from itself. For example, the proliferation of committed erythrocytes (Rc) is modu-
lated by the amount of erythrocytes present in the blood (Pb). The second term in
each equation accounts for the differentiation of HSCs into each committed cell pop-
ulation. The third term models the differentiation of committed cells into progenitor



















+ kcncC − kncmNc − µncNc (2.4)
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Equations (2.5)-(2.7) represent the three precursor cell types in the bone marrow,
and have similar form as Equations (2.2)-(2.4). They do not proliferate like committed
cells, instead they rely on the differentiation of committed cells. This process is
modeled by the first term of Equations (2.5)-(2.7). The second term, accounts for
the movement of each precursor cell into the peripheral blood, where they become
functioning cells. The difference in sizes of each compartment scales the parameter,



















Nm − µnmNm (2.7)
The PB equations that arise from the movement of precursor cells are given in
Equations (2.8)-(2.10). The first term in each accounts for the movement of precursor
cells out of the BM decay and the final models natural decay. The parameter vb, is
used like vm above , to scale the change concentration due to the shift of cells to the
blood compartment. The ratio of vb to vm is determined by the ratio of the blood


















Nm − µnNb (2.10)
Last, we model the presence of CD34+ cells in the PB by Equation (2.11).




proliferation is modulated by the amount of HSCs in the BM and the amount of
CD34+ cells in the PB. The second term in this equation is similar to the third term










(C − P )− µpP (2.11)
We refer to this model as the normal donor model, as it accounts for dynamics in a
healthy person. The parameters were chosen to match physiological blood cell counts,
erythrocytes account for 3-4 million cells/µL of PB, white blood cells account for 3-8
thousand cells/µL of PB, and platelets account for 150-250 thousand cells/µL of the
PB. We allow the range of PSCs to be broad, from 1-15 cells/µL, because our normal
donor data shows variability in these levels for healthy individuals. Less is known
about specific concentration of cells in the BM, so these dynamics were fit based on
relative numbers to each other. For example, the ratio of committed erythrocytes to
committed white blood cells was fit to be about 1:5. Also, because erythrocytes in
the blood have a higher half-life than other cells present the numbers of committed
erythrocytes in the BM are fit to have the lowest concentration.
Table 1 shows the resulting steady state of the normal donor model, which corre-
sponds to homeostasis in a healthy person. The percentage contribution of cell types
in the BM in Table 1 is calculated assuming that 60% of BM is not accounted for in
the model. This portion of the BM includes cells that become lymphocytes and other
immune cells not accounted for, as well as the portion of BM that is not functioning
in the process of hematopoiesis, such as fat cells. The parameters that give rise to
14
Steady State Value Effective Percentage
Variable (cells/µ L) of Compartment
HSCs (C) 222.88× 103 8.41%
Committed RBCs (Rc) 101.83× 103 3.84%
Committed Platelets (Lc) 243.32× 103 9.17%
Committed WBCs (Nc) 480.18× 103 18.10%
Differentiated RBCs (Rm) 41.56× 103 1.57%
Differentiated Platelets (Lm) 31.74× 103 1.20%
Differentiated WBCs (Nm) 39.47× 103 1.48%
PSCs (P ) 0.00245× 103 < 0.001%
RBCs (Rb) 3, 325.09× 103 93.61%
WBCs (Nb) 4.93× 103 0.14%
Platelets (Lb) 222.16× 103 6.25%
Table 1. Steady state values and percentages of cells in associated compartments for
the non-diseased donor model. In the percentage of cell types, the total BM
is assumed to include cell types modeled here and fat cells, other parts of the
bone marrow present that do not function in the process of hematopoiesis,
and those that make up the cell line that contributes to lymphocytes in the
blood. We assume that 40% of the blood is accounted for.
the homeostasis state are given in Table 2. While a healthy person wound not likely
undergo treatment, we use the normal donor model to set a baseline for continuing
model development. In particular, the steady state fit will be used as a starting point
for parameter sampling used to create a population of individuals with lymphoma.
2.2.2 Modeling Filgrastim Dynamics
We continue the modeling process by introducing the drug Filgrastim (Df ) into
the system. Filgrastim effects the proliferation rate of HSCs and committed neu-
trophils in the BM, as well as the movement of HSCs into the PB. This interaction
is indicated in Figure 1 by a single star. The drug also causes the committed cell
populations to move into the periphery where they are considered among the CD34+
cell population, indicated in Figure 1 by gray-dashed arrows.
We track relative Filgrastim drug effectiveness using Equation (2.12). The dosing
of the drug is modeled using Sm(t) = 1/(1 + e
−50(t0−mod(t,t0+tx))). This is function is
15
Parameter Value Description
sc 3.25 Source rate of HSCs
src 12.2 Source rate of committed RBCs
slc 3.8 Source rate of committed Platelets
snc 3.4 Source rate of committed WBCs
sp 3.0 Source rate of PSCs
kcp 0.0001 Rate at which HSCs move into the periphery
kcrc 0.2 Rate at which HSCs differentiate into committed RBCs
kclc 1.2 Rate at which HSCs differentiate into committed Platelets
kcnc 0.05 Rate at which HSCs differentiate into committed WBCs
krcm 4.0 Rate at which committed RBCs become pre-RBCs
klcm 0.9 Rate at which committed Platelets become pre-Platelets
kncm 0.3 Rate at which committed WBCs become pre-WBCs
krmr 8.0 Rate at which pre-RBCs move into the PB
klml 3.5 Rate at which pre-Platelets move into the PB
knmn 0.9 Rate at which pre-WBCs move into the PB
µc 0.45 Natural decay rate of HSCs
µp 2.0 Natural decay rate of PSCs
µrc 3.1 Natural decay rate of committed RBCs in the BM
µlc 2.0 Natural decay rate of committed Platelets in the BM
µnc 2.0 Natural decay rate of committed WBCs in the BM
µrm 1.8 Natural decay rate of committed pre-RBCs in the BM
µlm 3.4 Natural decay rate of committed pre-Platelets in the BM
µnm 3.4 Natural decay rate of committed pre-WBCs in the BM
µr 0.02 Natural decay rate of RBCs in the PB
µl 0.1 Natural decay rate of Platelets in the PB
µn 0.4 Natural decay rate of WBCs in the PB
vb 5 Relative size of the PB compartment
vm 1 Relative size of the BM compartment
c∞ 5000
Controls the effectiveness of the amount of RBCs in the PB to regulate the
source of committed RBCs
r∞ 4000
Controls the effectiveness of the amount of RBCs in the PB to regulate the
source of committed RBCs
l∞ 200
Controls the effectiveness of the amount of Platelets in the PB to regulate
the source of committed Platelets
n∞ 10
Controls the effectiveness of the amount of WBCs in the PB to regulate the
source of committed WBCs
p∞ 15
Controls the effectiveness of the amount of HSCs in the BM and PSCs in the
PB to regulate the source of PSCs in the PB
Table 2. Parameter values for the steady state dynamics of a non-diseased donor. Use
of these parameter values yields homeostasis in the non-diseased donor, values
given in Table 1.
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Fig. 2. Filgrastim drug dynamics that correspond to t0 = 6, tx = 18, xf = 1.5,
τ1f = 0.2 and τ2f = 0.025. Filgrastim was given for eight doses starting at day
two.
one for the six hours a day that the drug is entering the system and zero otherwise. It
is smooth approximation to the Heaviside function with the mod function controlling
the on and off each day. In practice, the drug is injected instantaneously, however,
since subcutaneously injected drug will be absorbed slowly over time, we use Sm(t)
to model the uptake of drug into the body as happening over the span of six hours.
The value t0 = 6 indicates drug uptake time in hours and tx = 18 is the remainder
of the day. The two terms control the accumulation of drug up to the value xf . The
second terms controls the decay of the drug in the system. Figure 2 shows Filgrastim




= τ1fDf (xf −Df )Sm(t)− τ2fDf (2.12)
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In order to model the inclusion of Filgrastim in the system described previously,
we modify Equations (2.1)-(2.4) and Equation (2.11). Filgrastim is known to increase
the rate of proliferation and movement of HSCs out of the BM, and to increase the
proliferation rate of committed neutrophils in the BM and CD34+ cells in the PB[4,
44, 37, 45, 46].. Therefore, the parameters sc, sp, kcp, and snc in the original model are
changed. Specifically, the parameters are increased by a factor (1+kxfDf ) determined
by the level of drug in the system. For example, the source of HSCs in the BM, sc is
increased by an additive amount determined by the constant kscf multiplied by the
level of Filgrastim in the system There is a corresponding parameter that modulates
the effect of the drug for all four parameters. The updated equations are given in
Equations (2.13)-(2.17).
In addition to this rate increase, Filgrastim also initiates the movement of com-
mitted cells form the BM into the PB where they become part of the CD34+ cell
population. This is modeled by the inclusion of an additional term in Equations
(2.14)-(2.16) for the lost of the cells from the committed cells and three additional
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To mathematically model the collection process, we assume the patient has two
resting days, where they are in steady state and the doctors have time to run tests
establish baseline values and potentially predict difficulties to come. We then model
the injection of Filgrastim in the system for six hours a day for four days, during which
time cells react to the drug and reach biologically relevant values based on known
responses to the drug. After four days the collection process is started. Removal
of the cells is modeled in the Lb, Nb, and P equations as exponential decay based
on the concentration of cell type present during the collection process. During the
collection process, erythrocytes are returned to the PB, so a decay is not included
in this equation. Removal occurs for six hours a day for four days, during which
time Filgrastim drug administration is continued. Afterwards, collection ends and
Filgrastim drug administration is halted and the concentrations return to steady
state.
The normal donor model with Filgrastim treatment is fit such that adequate
collection number are obtained in up to three days and fit to data in which healthy
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Parameter Value Description
kscf 0.09 Effect of Filgrastim on the proliferation of HSCs (sc)
ksncf 2.5
Effect of Filgrastim on the movement of HSCs into the PB
(kcp)
krcpf 0.0025
Causes committed RBCs to move intot he periphery where
they become CD34+ cells in the presence of Filgrastim
klcpf 0.0025
Causes committed Platelets to move into the periphery where
they become CD34+ cells in the presence of Filgrastim
kncpf 0.0025
Causes committed WBCs to move into the periphery where
they become CD34+ cells in the presence of Filgrastim
Table 3. The parameters controlling Filgrastims effect on the non-diseased donor sys-
tem are given. These parameters are unit-less multipliers applied to the level
of drug in the system and affect only parameters that modulate processes
affected by Filgrastim.
individuals are donating stem cells for a bank of cells that can be accessed by physi-
cians. This gives rise to the drug parameters in Table 3. With these parameters the
normal donor model yields approximately 440 million CD34+ cells collected in four
days. These parameters are unit-less scalars on drug effectiveness that control the
strength of the given model components in response to the drug, indicated in the
description column.
2.2.3 Modeling Autologous Stem Cell Mobilization in Lymphoma Pa-
tients
Next, we modify the parameters in the model to represent the steady state of a
population of patients with lymphoma that plans to undergo ASCT. Latin-Hypercube
Sampling (LHS) of the parameter space around the chosen representative set for a
normal donor is performed in order to obtain sets of parameter values that correspond
to patients with lymphoma [47]. We use uniform sampling of parameters believed to
be governing the diseased state with the minimum and maximum of the distribution
being 15% less and 15% more than the parameter’s value in the normal donor model
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fit. We sample sc, kpc, kcpr, kcpn, and kcpl, which are the parameters that control the
rate of proliferation of HSCs in the BM. All other parameters are held constant to
the normal donor values throughout parameter selection and subsequent simulations.
Parameter sets are considered to represent a diseased individual if the following
hold:
• The functional size of bone marrow in the lymphoma patient (Tfl) is smaller
than that of the normal donor Tfn : Tfl < Tfn [48].
• The steady state value of erythrocytes in the blood of the lymphoma patient is
within [3× 106, 8× 106] cells/µL for the resulting transients[1].
• The steady state value of platelets in the blood of the lymphoma patient is
within [100× 103, 600× 103] cells/µL for the resulting transients[1].
If a parameter set created by LHS passes these conditions, the set is accepted
and simulations for collection are run. The parameter set can then be classified as
one that yields adequate CD34+ cell count for transplantation (satisfactory collection
set) or one that does not (poor collection set). Establishing a collection of patients is
a useful tool because it enables us to look at various ways in which the disease could
manifest and still give rise to biologically relevant dynamics and explore how these
differences in the disease effect the patient’s ability to donate HSCs.
2.2.4 Modeling Plerixafor Dynamics
Despite treatment with Filgrastim and collection for four days and beyond, col-
lection numbers of PSC is occasionally too low. In this situation, the lack of PSC in
collection yields would prove detrimental to patients in the transplantation process,
and, therefore, treatment would be postponed. Doctors rely on the use of Plerixafor,
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and expensive yet effective drug to aid the stem cell mobilization process [49]. Pler-
ixafor (Dp) is always given in conjunction with Filgrastim and the treatment process
is restarted in order to increase mobilization and obtain a collection yield that is ade-
quate for transplantation. The increased movement of HSCs into the PB this causes
is indicated in Figure 1 by double stars. Plerixafor effectiveness is modeled similar to
Filgrastim effectiveness. Equation (2.18) has the identical form of Equation (2.12),
but the xp and τ parameters governing the dynamics will be different (xp = 1.1,
τ1p = 0.2 and τ2p = 0.025). The other parameters remaining the same since the drug
administration is the same.
dDp
dt
= τ1pDp(xp −Dp)Sm − τ2pDp (2.18)
In order to model the effect of Plerixafor on the cells, we introduce a second sum
on the factor kcp(1 + kcpfDf ) in the equations for BM and PB stem cells. The term
becomes kcp(1 + kcpfDf + kcpcDp), where the parameter kcpc modulates the effect of
Plerixifar in combination with Filgrastim.
The final set of equations modeling the process of hematopoiesis with the effects
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2.3.1 Modeling Allogeneic Stem Cell Mobilization Using Filgrastim in
Normal Donors
The transients for a normal donor undergoing collection are given in Figure 3.
These transients are the result of the parameters given in Table 2 and Table 3. We see
that Filgrastim increases the levels of all cell types in the PB, but they stay within
biologically relevant ranges. The dynamics for cells in the BM that move directly
out into the blood. Differentiated cells are not shown in the figure. Their dynamics
are similar to those of the committed cells in the BM, with a different scaling. All
dynamics settle back down to steady state by day 20 of the simulations. Collection
of PSCs is occurring starting at day six and continuing through day nine. It is not
clear that anything is being removed in the transients because the removal process is
occurring at the same time as drug is being administered, and therefore the system is
quickly responding to the removal. With larger collection rate, which does not match
the data, collection is visible in the transients.
The drug response was fit such that stem cell collection yields cell numbers high
enough to be considered for transplantation. Normal donors typically yield adequate
CD34+ cell number for transplantation within three days, but patients tend to take
up to four or more days to yield enough cells. Therefore, we continue to simulate
for four days in order to allow for a baseline for collection that matches the required
number of days for diseased patients.
The collection dynamics can also be compared to data obtained in vivo, as shown
in Figure 4. The black ‘x’ indicates those donors that collected successfully over a
single day of collection. Data for collection each day was plotted for those that
collected two, three, and four days in green squares, red diamonds, and pink stars,
24
Fig. 3. The transients corresponding to collection is shown for the non-diseased donor
model. Parameters used for this simulation are given in Table 2. Initial con-
ditions are the steady state values given in Table 1. Filgrastim was given for
eight doses starting at day two.
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Fig. 4. Non-diseased donor data of collection numbers for one to four days of collection
are plotted. Black ‘x’s represent donors that collected in one day. Green, red,
and pink lines represent donors that collected in two, three, and four days,
respectively. The blue line is the mean of daily collection plotted as a single
donor. The blue bars indicate the standard deviation.
respectively. Data from the same patients are connected by appropriately colored
lines. The blue dots with bars show the mean and standard deviation of each day of
collection for all collections performed. The model results are plotted with the black
line and open circles . Given there is variability in the collection rates, the model
collects the same amount of cell each day.
We analyze the outcome of LHS from the non-disease donor model and classify
resulting patients as either poor or satisfactory collectors undergoing only Filgrastim
treatments. Out of a total of 1500 possible sets, 149 sets were considered biologically
acceptable to account for lymphoma. Table 4 outlines the results from the LHS by
identifying the mean, standard deviation, maximum, and minimum of the parameters
we altered. Of the 149 sets that were accepted, 84 collected a satisfactory number of
stem cells and 67 did not.
26
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Non-diseased donor model fit
Representative set of satisfactory collection
Representive set of poor collection
Threshold for adequate collection
Fig. 5. The representative sets acquired from LHS of parameter space of the non-dis-
eased donor fit are shown. The red (higher) curve shows accumulation of stem
cells using the parameters in the Satisfactory Collector column of Table 4, the
black (lower) curve shows accumulation of stem cells using parameters in the
Poor Collector column of Table 4, and the blue (middle) curve shows accumu-
lation of stem cells using the non-diseased donor fit (starting) parameters. The
dashed line indicates the threshold for adequate stem cell collection.
Figure 5 shows the results of the simulations with the representative set for
satisfactory collection plotted in red, the representative set for poor collection plotted
in black, and the normal donor model fit plotted in blue. The dashed horizontal line
marks the point at which 420 million cells were collected, the threshold for satisfactory
collection for 72 kgs, which we assumed was the weight of all of normal donor and all
patients [8, 50, 51, 52].
In order to analyze the effect of parameter changes on biological steady state, we
mathematically determine which parameters are correlated with each other. sc and
kclc were the only pair that found to be significantly correlated. We plotted these


































































































































































































































































































































































































































































































































































































































































cells collected, in Figure 6a. In this figure, satisfactory collectors are plotted with ‘x’
and poor collectors are plotted with ’o’.
Biologically relevant dynamics only arise when these parameters are directly
proportional. Given that there is no color pattern, we see that these parameters are
not driving collection numbers. Collection is dependent on the value of snc, which is
plotted in comparison to sc in Figure 6b. Higher value of the parameter snc correspond
to higher yield in stem cell collection.
2.3.2 Modeling Autologous Stem Cell Mobilization Using Filgrastim in
Patients
Next, we sample drug parameters 25% above and below both the satisfactory
and poor collection representative sets to for the drug parameters in the proliferation
and differentiation terms. Physiologically, it is expected that individual patients
may have a different response to the same drug, so this sampling allows us to show
this variability in populations. From the satisfactory representative set, out of 100
parameter samples, 24 became poor collectors. Similarly, from the poor representative
set, out of 100 parameter samples, 35 became satisfactory collectors. Table 5 outlines
the results of this sampling. The mean, standard deviation, minimum and maximum
of the resulting collections are given.
Figure 7 shows the collections numbers versus the parameter ksncf . This pa-
rameter has the most effect on collection results. This lead use to hypothesize when
the patient is on Filgrastim the most effective mechanism for increasing total stem
cells collected is by increasing the committed white blood cells moving into the pe-
riphery as CD34+ cells. As you increase the patients’ committed white blood cell
proliferation rate in response to the drug significantly increases collection numbers.
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Fig. 6. For each, parameter values are plotted with the point being marked by a color
based on the number of stem cells collected. For the top figure, points were
plotted at each (sc, sclc) combination in the sampling and colored by their
collection totals. For the bottom figure, points were plotted at each (sc, snc)
combination in the sampling and colored by their collection totals. Satisfactory
and poor collectors are indicated by x’s and o’s, respectively.
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Collection Results Mean Standard Minimum Maximum
(total cells) Deviation
Poor/Poor 378.9×106 22.6×106 336.6×106 418.1×106
Poor/Satisfactory 474.4×106 12.7×106 421.2×106 463.8×106
Satisfactory/Poor 402.5×106 11.5×106 385.6×106 419.8×106
Satisfactory/Satisfactory 474.4×106 31.8×106 420.9×106 530.8×106
Table 5. This table outlines the results of sampling drug parameter space. The first
two rows are associated with parameter sets created by sampling drug pa-
rameters kscf , ksncf , krcpf , klcpf , and kncpf . The last two rows correspond to
sampling over the same drug parameters, but with the satisfactory represen-
tative set. The mean, standard deviation, maximum and minimum values of
the resulting total cell collection are shown. The first label in column one
indicates which respresentative set was used for sampling. The second label
indicates the collection result after altering the response to Filgrastim. For
example, the second row displays the statistics for the parameter sets that
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Satisfactory Representative Sets
Poor Representative Sets
Fig. 7. The effect of drug parameter ksncf on collection in the poor and satisfactory
case. Like before, satisfactory collectors are shown with ‘x’ and poor with ‘o’.
Points in black are from the sampling using satisfactory representative set and
points in blue used the poor collector representative set for sampling.
Following the sampling of drug parameter space to determine how responses to
the drug Filgrastim vary between patients, we include the use of Plerixafor for patients
that originally did not mobilize well enough for collection to be successful. We fit the
parameter that models the patients’ response to the level of Plerixafor in the body
such that all but the very worst poor collectors become satisfactory collectors, since
this drug is highly effective. Figure 8 shows the results for one poor collector before
and after Plerixafor treatment.
2.4 Discussion
We mathematically model the stem cell mobilization and collection process un-
der Filgrastim and Plerixafor drug treatment regimens. After fitting the model to the
normal case, we use statistical sampling to account for variability of underlying phys-
iological dynamics in the model. The dependence of parameter values on biological
dynamics and response to the drug was also analyzed. We found that the parameter
32
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Fig. 8. This figure shows the results of Plerixafor salvage. Plerixafor in conjunction
with Filgrastim (solid line) increases the number of stem cells collected above
the threshold for collection. The long-dashed like is the accumulation of stem
cells before Plerixafor was used.
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kclc (the rate at which HSC differentiate into committed platelets) must be directly
proportional to sc (rate of self-renewal of HSC in the bone marrow) for the associ-
ated transients to be biologically relevant. The parameter snc (rate of self-renewal of
immune cell precursors in the bone marrow) was also found to be a driving force in
collection. If this parameter is not high enough, collection is typically not adequate.
In addition to analyzing the dynamics driving cellular interactions, representative
parameter sets that account for satisfactory and poor collectors are determined and
their parameters are used to analyze the response to Filgrastin. Specifically, we
use statistical sampling to vary the parameters associated with Filgrastin treatment
with both the satisfactory and the poor collector representative set. We analyze
the resulting parameter sets and transients and determined that the drug parameter
ksncf (increase of white blood cell replenishment due to Filgrastin) has the most effect
on collection numbers, a result which is biologically relevant. Collection was most
affected by changing snc and ksncf . Overall, Filgrastim presence on these processes
caused more committed white blood cells move into the periphery. We hypothesize
that the increase in this parameter cause a rise in CD34+ cells in the PB and thus,
collection is impacted positively.
Representative parameter sets that account for satisfactory and poor collectors
lead to a baseline over which to analyze variability in response to the drug Filgras-
tim in the system. Specifically, we account for variability in collection under drug
treatments by obtaining parameter sets using both a satisfactory and a poor collector
representative set. We determined that the drug parameter ksncf had the most ef-
fect on collection numbers, and we believe that this is due to the fact that committed
white blood cells move into the periphery when Filgrastim is present. We hypothesize
that the increase in this parameter cause a rise in CD34+ cells in the PB and thus,
collection is impacted positively. Following the sampling of Filgrastim drug affects
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on the dynamics, we analyze the inclusion of Plerixafor drug use in conjunction with
Filgrastim. Plerixafor rescue is a highly successful method for increasing collection
in patients that do not mobilize well, regardless of whether poor response to drug or
underlying disease dynamics are driving low collection.
Following the sampling of Filgrastim drug effects on the dynamics, we simulated
the inclusion of Plerixafor drug used in conjunction with Filgrastim. Plerixafor rescue
is a highly successful method for increasing collection in patients that do not mobilize
well. With this model we see that it is effective regardless of whether poor response
to drug or underlying disease dynamics are driving low collection.
Clinically, this model is useful in that it lends important quantitative insights
into the dynamics of HSC mobilization. Given that collection is driven by rate of
self-renewal of immune cell precursors, patients that do not mobilize adequate HSCs
for stem cell transplantation may have a lower rate of immune cell precursor self-
renewal. Also, the model indicated that background levels of these cell types are
normal in a patient, if the relationship between the rate at which HSC differentiate
into committed platelets and rate of self-renewal of HSC in the bone marrow are
linearly related. Therefore, if patients do not have normal background levels before
treatment, these rates may not be appropriately aligned. If this could be tested and
treated it may address underlying issues that could effect the ability for that patient
to collect.
Currently, we use a fixed rate of collection in order to focus on the how the
changes in the underlying dynamics drive changes in collection numbers. In order to
quantitatively match donor data the model would have to be altered to capture the
trend that collection numbers drop significantly following the first day of collection.
This base model gives insight into the driving dynamics of collection and if the first
step in finding a method to determine optimal drug protocols to increase collection
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numbers. Future work on this project would allow us to better capture the varying
day to day collection rather than focusing on overall collection numbers. Additionally,
we could adapt the model to account for stem cell loss in the periphery to organs and
then model the injection of stem cells back into the PB and analyze how well the
system returns to steady state. This would allow us to focus on effectiveness of the
stem cell transplantation rather than the collection.
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CHAPTER 3
MATHEMATICAL MODEL OF SYSTEMIC MEDIATORS IN THE
INFLAMMATORY PROCESS OF WOUND HEALING
3.1 Introduction
During the wound healing process, many cells and signaling molecules interact
to clean the wound site and repair the damaged tissue. When this process progresses
normally, an orderly inflammatory response removes the debris and pathogens and
allows the repair phase to begin and the wound to heal. However, trauma or diseases,
such as diabetes, can impair these cell interactions and signaling mechanisms. In
particular, an impaired inflammatory response can lead to chronic skin wounds, and
caring for chronic wounds is a challenging and very costly medical problem [53].
Prolonged wound healing requires extensive care, leads to patient suffering and high
health care costs, and affects more than six million people per year [54, 55]. The cost
to care for chronic skin wounds exceeds $25 billion per year in the US [53]. Even
in the absence of co-morbidities, wound healing does not always proceed normally.
In trauma patients with large wounds, complications can lead to sepsis, multi-organ
failure, and even death [56].
The body’s natural response to a wounding event involves four phases: hemosta-
sis, inflammation, proliferation, and remodeling [57]. Understanding the interplay
between the four stages is essential to understanding the overall process. Because
many complications in wound healing are marked by unresolved inflammation, we
used mathematical modeling to analyze the dynamics of the inflammatory stage with
and without the effects of the systemic mediator estrogen. There is evidence that
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this hormone is highly involved in regulating inflammation, along with several other
components of the wound healing process [56, 9, 58, 59, 10, 60, 61, 62, 63, 64, 65, 11,
66, 67]. Initially, we model the dynamics of the inflammatory phase without other key
components of wound healing, in order to understand the role of different immune cell
populations. Following this study, the inflammatory phase model will be included in
a full wound healing model where the inflammatory, repair, and remodeling phases of
wound healing will be analyzed. The full model, including the effects of estrogen, is a
necessary step towards a model that accounts for gender that can be used to develop
new treatment strategies for patients with chronic wounds.
Estrogen receptors are present on many of the key cells involved in wound healing,
such as epidermal cells, neutrophils, and macrophages [59, 10, 11, 66]. Therefore,
estrogen can interact with the critical cells involved in the wound healing response,
and thus modulate the wound healing process. Overall, the absence of estrogen slows
healing [9, 10, 11]. Systemic effects of estrogen on the body are gender and age specific,
and therefore, the model with a non-zero estrogen parameter value represents a pre-
menopausal female and the model with a zero estrogen parameter value represents
males and post-menopausal females.
Mathematical models of wound healing have been used to understand various
aspects of wound healing, including wound contraction, infection, diabetic compli-
cations, inflammatory response, and the role of oxygen in healing [68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84]. Wound healing is complex and
multiple mathematical techniques have been used to understand different aspects of
the process. Modeling approaches include the use of ordinary differential equation
(ODEs) [68, 69, 70], partial differential equation (PDEs) [72, 73, 74, 75, 76, 77, 78,
79, 80, 81, 82], and agent based modeling (ABM) [83, 84]. A review of modeling
efforts in the area of wound healing, [71], addresses the different aspects of wound
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healing and discusses the use of the modeling techniques relevant to the field. Most
models using PDE techniques analyze spatial wound dynamics, such as contraction
[75, 76, 79, 81] or angiogenesis and oxygen distribution [73, 74, 78, 82]. Because PDE
models are computationally expensive, these models do not focus on the complex
interactions between different inflammatory cells, nor do they consider the roles of
systemic mediators in the healing process.
In our previous work, Menke et al., we presented an ODE for the dynamics of
the inflammatory response and fibroblast activity and the resulting wound closure
rate is considered [69]. In general, we choose to work with an ODE model because
we are concerned with capturing the relative timing and strength of the various cells
and chemical signals during the phases of healing. The focus of this chapter is on
understanding when the entire inflammatory phase subsides and is not concerned with
the intra-wound complexities of the distribution of cells or the wound geometry. The
ODE modeling paradigm continues to be relevant for our work. Segal et al. extends
the Menke et al. model by accounting for the late stage deposition of collagen due
to fibroblast dynamics [70]. The new inflammatory phase model reported here is
the first to focus on the role of specific inflammatory cells, such as neutrophils and
macrophages, while accounting for systemic mediators.
3.2 Model Development
Neutrophils are the first responders of the inflammatory response and function
mainly by clearing debris and pathogens [54, 85, 86, 87]. Subsequently, activated
macrophages enter and continue to clear debris and pathogens, as well as clear apop-
totic neutrophils that remain at the wound site. Once the wound is clean and the
neutrophil numbers have been reduced, the next stage of wound healing can begin
[88, 89].
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In our previous models [70, 90, 91], the total inflammatory response is rep-
resented as a single variable. However, this is not detailed enough to model the
different roles the various inflammatory cells play during the healing process or the
different effects systemic mediators have on each type of inflammatory cell. Including
a separate variable for each cell population (macrophages and neutrophils) leads to a
more biologically accurate model. This is a necessary step in developing a model that
properly responds to changes in estrogen. Therefore, the equation for total inflamma-
tion from Segal et al. [70] is replaced with separate equations that model activated
macrophage (M) and neutrophil (N) activity. We also added a variable for the level
of debris in the wound (Pt). Pathogen levels, represented by (P ) are modeled as in
Segal et al. [70]. The interactions between the variables in this inflammatory phase
model are depicted in Figure 9. The variables do not represent exact total cell counts
or concentrations. Instead, they are a relative measure of the populations activity.
Therefore, the variables are not fit to exact numerical values, but instead parame-
ters are selected to qualitatively match the dynamics of the inflammatory phase of
normal healing. The models results will be validated by a comparison to experimen-
tal data for healing with neutrophils and macrophages individually blocked [92, 93].
Additionally, we altered terms to represent the effect of estrogen in the system and
compared our results qualitatively to published experimental data generated using
estrogen treated animals.
3.2.1 Pathogen Equation
In order to derive the new subsystem of equations we start with the variables P ,
N and M to represent pathogens, activated neutrophils and activated macrophages,
respectively. The pathogen equation, Equation (3.1), accounts for pathogen growth
and pathogen removal by both inflammatory cell types. The first term of the equation
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Fig. 9. Model schematic for the inflammatory response of wound healing. P , Pt, N
and M , represent Pathogen, debris consisting of Platelets, Neutrophils and
Macrophages, respectively. Arrows represent up-regulation and bars represent
destruction or inhibition.
represents the logistic growth of pathogen with carrying capacity, p∞, and growth rate,
kpg. The second term represents the degradation of pathogen by the local background
immune response, such as antibodies. This term was derived by assuming that the
local response is in quasi-steady state. The parameters kpg, sb, µb, and kbp are the
rate constants for the local background immune response. Reynolds et al., 2006
provides additional details [90]. The final terms in the pathogen equation, −kpnPN
and −kpmPfi(M,N), account for the phagocytosis of pathogen by each of the immune
cell populations [56, 92, 86, 87, 89, 93, 94, 95]. The inhibition on the second term is
added in order to account for neutrophil activity causing oxidation of the environment.
In turn this inhibits the ability of macrophages to clear pathogen [89, 96]. The
inhibition term has the form fi(x,N) =
x
1+(N/N∞)
2 , where the parameter N∞ controls
the level of N at which inhibition reduces macrophage activity by fifty percent. This












− kpnPN − kpmPfi(M,N) (3.1)
3.2.2 Debris Equation
The variable Pt accounts for signaling to the inflammatory cells due to the ac-
cumulation of debris at the wound site. When wounding occurs and blood vessels
are severed, the matrix is damaged and a large amount of debris is dumped into
the wound site. This debris includes red blood cells, white blood cells, degranulated
platelets, damaged extracellular matrix, bacteria, and foreign bodies. The debris
variable is named Pt due to the significant involvement of platelets in initiating the
inflammatory response, but all of these components of the debris are activators of the
inflammatory phase [85, 86]. Once the inflammatory cells are activated and recruited,
they remove the debris [54, 56, 92, 85, 86, 87, 93, 94, 95]. Neutrophils are typically
the first inflammatory cells to respond and they dominate this process [93]. In the
absence of neutrophils, macrophages are capable of removing the debris [89, 93, 95,
97]. The first two terms of the Pt equation, −kptnPt and −kpmPfi(M,N), model the
removal of debris by the inflammatory cells, see Equation (3.2). As in the pathogen
equation, macrophage removal of debris is inhibited by neutrophil activity.
dPt
dt
= −kptnPtN − kptmPtfi(M,N) + µN − µptPt (3.2)
The third term, µnN , represents the contribution of dying neutrophils to the
amount of debris present in the wound. Macrophages gradually exit the wound site
through the process of apoptosis and also exit via lymphatic drainage. Thus, they
leave very little debris behind [94]. The last term, −µptPt, accounts for the intrinsic
decay of signaling due to the removal of debris.
42
3.2.3 Activated Macrophage Equation
To derive the macrophage equation, we first describe the behavior of resting fixed
tissue monocytes (MR) and activated wound M1 macrophages (M). We focus on the
inflammatory phase of wound healing, during which the main role of macrophages
is pro-inflammatory. Thus, our macrophage variable represents classical activated
macrophages, designated as M1 macrophages [98]. The basic reactions for the inter-
action between these variables are given in Table 6. It is assumed that when a resting
fixed tissue monocyte encounters either foreign material, a pro-inflammatory medi-
ator (such as TNF), or a byproduct of neutrophil activity (such as reactive oxygen
species), it becomes activated [99]. This activation process occurs at a rate given by
R1(Pt, P,M,N) = kmptPt + kmpP + kmmM + kmnN . The first and second terms of
the R1(Pt, P,M,N) equation represents the activation of resting fixed tissue mono-
cytes by the presence of debris and pathogen, respectively [86, 100]. The third term
of the equation represents the activation of resting fixed tissue monocytes by the
pro-inflammatory cytokines released by the activated macrophages [86, 95]. The fi-
nal term accounts for the further activation of the resting fixed tissue monocytes by
neutrophils due to neutrophil byproducts [94, 100, 101, 102, 103].
When a resting fixed tissue monocyte encounters a protein or cell type capable
of activating it, it becomes an activated macrophage. These monocytes move from
the resting population to the activated macrophage population at the rate µmr, as
seen in Equation (3.3)-(3.4).
There is a natural source in the first equation to account for production of resting
fixed tissue monocytes from the bone marrow, the first term in Equation (3.3). The
final two reactions, indicated in Table 6, account for the intrinsic decay of both




kmptPt+kmpP+kmmM+kmnN−−−−−−−−−−−−−−−−−−→M Activation of resting fixed tissue monocytes (MR)
is induced by the presence of debris (Pt) and
pathogen (P ), by positive feedback from the ac-
tivated macrophages (M) via pro-inflammatory cy-
tokines and the harmful byproducts of neutrophils
(N) function. The neutrophils associated activa-
tion is assumed to be nonlinear.
∗ smr−−→MR Source of MR
MR
µmr−−→ Intrinsic decay of MR
M
µmr−−→ Intrinsic decay of M
Table 6. Reaction kinetics of the resting and activated macrophages. These interac-




= smr − µmrMR −R1(Pt, P,M,N)MR (3.3)
dM
dt
= R1(Pt, P,M,N)MR − µMM (3.4)
Since the activation process of resting fixed tissue monocytes (MR) is rapid once
it begins, we can assume that the variable MR is in quasi-steady state and reduce
Equations (3.3)-(3.4) to a single activated macrophage equation, Equation (3.5) [94].









3.2.4 Activated Neutrophil Equation
The derivation of the neutrophil equation follows the same process as the macrophage
equation. However, the activation term is developed for neutrophils by assuming that
debris and pathogen are the only activators of neutrophils [56, 85],[86]. Therefore,
the rate of activation is R2(Pt, P ) = knptPt+knpP . We again use a quasi-steady state
assumption on the resting population to form the activation term for the activated
neutrophil equation, Equation (3.6).
Macrophages present at the wound site actively remove the neutrophils that are
laden with bacterial and debris and have moved into a state of apoptosis [54, 106]. The
term −kptmPtfi(M,N) is added to the neutrophil equation to model this interaction.
Again, the adverse environment of a wound with high neutrophil activity inhibits the
macrophage activity in the wound and therefore, we add inhibition to this term. The





µnr +R2(Pt, P )
− knmfi(M,N)− µnN (3.6)
3.3 Modeling the Effect of the Systemic Mediator Estrogen on Inflam-
mation
To account for estrogens effect on the inflammatory process, we introduced an
estrogen parameter, E, with E = 0 representing no estrogen and E = 1 representing
normal estrogen. A well accepted characteristic of neutrophils is that they stick to
the walls of blood vessels surrounding the wound site and move through the vessels
into the wound [56]. When estrogen is present the infiltration of neutrophils into
the wound site decreases [9, 59]. In the first term of Equation (3.6), we account
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for the activation of resting neutrophils and determine the level neutrophil activity
in the wound. By inhibiting this term, we effectively inhibit the total activated
neutrophil activity in the wound. We use the same form of inhibition as we did with




The parameter EN∞ controls the level of estrogen that gives rise to a fifty percent
reduction in activation (and influx). The other terms in the neutrophil equation are






µnr +R2(Pt, P )
, E
)
− µnN − knmNfi(M,N) (3.7)
There is also evidence that estrogen increases the phagocytic ability of neu-
trophils and macrophages [9, 59]. Therefore, we add a multiplier to all phagocyto-
sis terms in the pathogen and debris equations, Equations (3.8)-(3.9), respectively.
This multiplier is set to one when estrogen is off and greater than one when es-
trogen is on. The pathogen phagocytosis terms become −kpnPN(1 + kenE) and
−kpmPfi(M,N)(1 + kemE). The parameters ken and kem control the relative ef-
fect of estrogen on neutrophils and macrophages, respectively. Similarly, the phago-
cytosis terms for debris are also modulated by estrogen, −kptnPtN(1 + kenE) and
−kptmPtfi(M,N)(1 + kemE) . The updated equations for pathogen and debris are










− kpnPN(1 + kenE) (3.8)
− kpmPfi(M,N)(1 + kemE)
dPt
dt
= −kptnPtN(1 + kenN)− kptmPtfi(M,N)(1 + kemE) + µnN − µptPt (3.9)
There is also evidence that estrogen inhibits the differentiation rate of fixed tissue
monocytes into activated M1 macrophages that clear the wound following neutrophil
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infiltration [9]. More specifically, the presence of estrogen down-regulates the ef-
fectiveness of macrophage recruitment of additional macrophages. While this may
seem detrimental to wound healing, it is acting as a mediator to the inflammatory
response, and therefore decreases the likelihood that a wound will enter into a stage
of chronic inflammation (6). The rate constant for macrophage activation by its own
cytokines becomes fEM(kmm, E) =
kmm
1+(E/EM∞)2
, where EM∞ plays the same role for
macrophages as EN∞ does for neutrophils. These parameters are not set to be equal
because, as with ken and kem, we do not assume that estrogen affects neutrophils and








with R1(Pt, P,N,M) = kmptPt + kmpP + fEM(kmm, E)M + kmnN .
3.4 Final Equation
The full model that includes the effects of estrogen gives the final form of our











− kpnPN(1 + kenE) (3.11)
− kpmPfi(M,N)(1 + kemE)
dPt
dt






µnr +R2(Pt, P )
, E
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with the rate equations R1(Pt, P,N,M) = kmptPt + kmpP + fEM(kmm, E)M + kmnN
and R2(Pt, P ) = knptPt + knpP and the inhibition functions fEN(x,E) =
x
1+(E/EN∞)2





Immediately following wounding, blood floods into wound site and brings in
circulating red blood cells, neutrophils, and platelets. The trauma that created the
wound, unless surgical, will introduce pathogens to the wound site. Therefore, the
initial conditions for all wounds have nonzero neutrophils (N), debris (platelets and
clot) (Pt) and pathogens (P ) [85, 86]. The initial value of the debris and pathogen
variables will indicate the severity of the wound. Because neutrophils originate in the
blood, and the concentration in the blood is independent of the wounding event, they
are always set to the same level initially [107]. We use Pt = 2, P = 0.1, N = 0.1, and
M = 0 as the standard wound initialization.
3.6 Parameter Estimation
During normal healing there are various phenomenon that occur: neutrophil
activity peaks between day one and two [56, 92, 86, 89, 93] and macrophage activity
peaks between days three and five [108]. Given that these dynamics hold for various
patients who likely do not have the same underlying immune response rates, we did
not seek a single parameter set to satisfy these conditions but rather a collection of
sets that satisfy conditions for both the parameters and their associated transients.
First, we select parameter sets that satisfied the conditions for a stable fixed
point corresponding to health, (Pt, P,N,M) = (0, 0, 0, 0). Note that while the initial
condition for N is nonzero due to influx from the blood during injury, in the healthy
state N is zero since neutrophil activity locally resolves to its pre-injury level. Lin-
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Parameter Name Description Value
kpg Pathogen growth rate 14.4/days
p∞ Carrying capacity of the pathogen population 20 (106/cm3)
kbp Activation of local background immune response by pathogen 0.2/days/P-units
sb Source of background local response 0.12 M-units/days
µb Intrinsic decay of local response 0.048/days
kpb Destruction of pathogen by local background response 14.4/M-units/days
Table 7. The model parameters for the local background immune response are given.
These parameters were unchanged during the parameter space sampling.
These parameters were set to their values from [Rey2006]
earization of equations about the health fixed point yield parameter conditions for
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Our focus is on a wound started via an increase in debris and not due to a
pathogen insult. Also, because of the minimal role that the background local re-
sponse plays in the general dynamics, the parameters associated with the background
response in this inflammatory phase model are held fixed at their values from the orig-
inal inflammation model, Reynolds et al. [90], see Table 2. The first condition for
health is satisfied with the parameters fixed at these levels.
Latin Hypercube Sampling is then used to determine most of the remaining pa-
rameters. One parameter value from each of conditions (2) and (3) for stable health,
kmm and knpt, respectively, are not determined using Latin Hypercube Sampling.
Instead, they are sampled from a uniform distribution such that the associated con-
ditions are satisfied. To determine the value for kmm, we first find µm, µmr, and smr
for each parameter set and then use their ratio from the second condition to determine
the maximum for kmm over each parameter set. The parameter kmm is then selected
from a uniform distribution with this value as the maximum. The same process is
completed to determine knpt.
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Additionally, parameters that have known biological values or constraints are
selected to satisfy those conditions, see Table 3. Also, we enforce a range on N∞
that is determined by the source and decay rate of neutrophils. This is implemented
to ensure that the strength of the inhibition by neutrophils is appropriate. During
our initial sampling, we used the same minimum and maximum for all parameters
that we do not put restriction on, but we were not successful at finding a significant
number of sets. We used the sets we did find to refine the maximums and minimums
to the values in the table. If no minimum is explicitly stated we use 0.0001.
Our sampling is performed using the Latin Hypercube Sampling method devel-
oped by Marino et al. [47]. Parameter space sampling is used to formulate a set of
feasible parameter values, each set is then used in a model simulation with the initial
conditions stated above and accepted if it satisfies the following conditions:
1) The peak for neutrophils was between 0.75-2.75 days [56, 92, 86, 89, 93],
2) The peak for macrophages was between 2.75 -6.25 days [108], and
3) Macrophage levels dropped below 0.1 by day 20.
The ranges on the peak times are broader than those stated in the literature.
This is for two reasons: First, experimental data is not collected frequently enough
to determine exact thresholds on these ranges, so we extend them in both directions.
Second, the repair phase and the anti-inflammatory mediators triggered during the
inflammatory stage are not modeled in this subsystem. To account for this lack
inhibition we lengthen the range by accepting sets with later peaks. The final check
on macrophage activity levels is to ensure that the resulting transient resolved to
the healthy fixed point in a timely manner. Overall these conditions produce 1369
acceptable sets out of a sample of 100,000 possible sets.
In our previous models, estrogen was not explicitly modeled, but calibration
and validation was based on published data for normal healing in experiments using
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female animals [69, 70]. Therefore, to determine values for the estrogen parameters
we perform a similar process as before, but we turn estrogen off and accepted sets
only if the resulting transient changes appropriately. We test this estrogen parameter
estimation method with various sets from the initial 1369 sets determined from the
normal dynamics and note similar changes in transients when estrogen is removed.
However, to determine the final set of acceptable estrogen parameters we focus on
one representative parameter set from the 1369 parameters sets we found for normal
healing to determine the estrogen parameters.
We cannot use the mean of the 1369 parameter sets as the representative set
since it does not satisfy the conditions for health. Instead, we determine the average
behavior of each variable versus time, which we refer to as the mean of the tran-
sients. We then choose a parameter set that minimizes the Euclidean norm between
its associated transients and the mean of the transients, and we refer to it as the rep-
resentative parameter set. This set is used when determining the estrogen parameter
sets.
It is documented that the influx of neutrophils decreases slightly when estrogen is
present [9, 59], but there is not sufficient understanding for the changes in macrophage
activity in the presence of estrogen to implement a condition on the macrophage
transients. Therefore, we set our condition for acceptable sets as those that give rise
to increase of 5-15% in the peak of neutrophils when estrogen is removed and the
conditions for a stable healthy fixed point are still satisfied. The range of 0.0001
to 10 is used on all estrogen parameters during sampling. Sets are accepted if their




This inflammatory phase model of wound healing consists of a fixed set of equa-
tions with a collection of 1369 acceptable parameters sets. Below, we describe the
behavior of this model. Finally, we investigate the behavior of the model in response
to estrogen and cortisol.
3.7.1 Pt/P/N/M System without Systemic Mediators
The transients of the inflammatory equations of the Pt/P/N/M system behave
similarly to the transient of the inflammatory equation in Reynolds et al. [90] and
satisfy the conditions set for parameter fitting. Figure 10 shows sample transients
from the normal healing sets with estrogen present (E = 1). Given that most of
the pathogen-associated parameters are fixed, there is very little variability in the
pathogen transients.
Figure 11 illustrates the main differences in the representative sets transients
and the mean of transients found by averaging over the transients associated with all
1369 sets. The neutrophils transient for the representative set is similar in shape to
the mean of the transients, but with a slightly lower peak neutrophil level. However,
the macrophage transient from the representative sets peaks later than the mean of
the transients with a slightly higher macrophage level at the peak. The mean of the
transients also has a longer tail. The differences between P and Pt were minimal.
The values of the parameters in the representative set and the statistics from the
acceptable parameter sets are given in Table 8. Additionally, the conditions used for
fitting each parameter are also given in this table.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 10. Sample transients of the inflammatory subsystem are shown. The sets used to
create these transients were randomly selected from the 1369 sets found using
normal conditions (E = 1), with initial conditions Pt = 2, P = 0.1, N = 0.1,
and M = 0.
Fig. 11. A comparison of the mean of transients and the representative set is shown.
The mean of the transients for neutrophils and macrophages are plotted in
blue. The transient from the representative set are plotted in black (dashed).
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Data Populations Mean Minimum Maximum Standard




Macrophages 4.08 2.77 6.21 0.80
Neutrophils 0.91 0.75 1.69 0.13
“Representative”
parameter set
Macrophages 4.37 - - -
Neutrophils 0.88 - - -
No Macrophage
Experiment
Neutrophils 1.22 0.8 2.76 0.25
No Neutrophil
Experiment
Macrophages 2.82 1.41 5.32 0.67
Table 9. Peak time for the normal condition of the wound healing model is shown
to validate the experiments. The mean, maximum, minimum, and standard
deviation of the transients of all final parameter sets from the normal con-
ditions simulations (E = 1), Representative set (column 4 of table 6), no
macrophage experiments (smr = 0), and no neutrophils experiments (snr = 0
and N(0) = 0).
parameter set, see Table 9. Though the parameter estimation allows for peaks time
ranging from 0.75-2.25 days for neutrophils, the acceptable sets have a narrower range,
0.75-1.69 days. The range for the macrophage peak is the same as the selection
condition. This is a validation of the resulting sets because neutrophil activity is
resolved before the anti-inflammatory effects associated with repair are significant.
Therefore, macrophages alone should be able to modulate the neutrophil activity
during normal healing. Additionally, anti-inflammation mediators will be needed to
achieve the normal dynamics for the macrophage population. For the representative
set, the peak occurs within one standard deviation of the peak of transients.
We determine the correlation coefficient for each pair of parameters that are
varied. In general, there is not a strong correlation between parameters. Only two
parameter pairs have correlation coefficients greater than 0.5. The correlation co-
efficient for snr and N∞ is 0.80 and snr and knpt was −0.67. Figure 12 shows the
relationship between these parameter pairs. The plot on the left shows the positive
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Fig. 12. Accepted parameter sets are shown and colored by the maximum neutrophil
level. The plot on the left has a point plotted as (snr, N∞) for each of the
1369 accepted parameters. The points are colored by the value of N a its peak
for that particular set. The point on the right is the same, but with points
plotted as (snr, knpt).
correlation between snr and N∞. This plot has a point plotted at (snr, N∞) for each
of the 1369 accepted parameters. The points are colored by the value of N at its peak
for that particular set. The right plot shows the inverse relationship between snr and
knpt, using points plotted at (knpt, snr). Most of the sets have peak values in the lower
range (0.1-0.2, blue-light green). The peak value color pattern in more structured in
the plot on the right, indicating a stronger dependence of the peak value on the value
of knpt than N∞.
The relationship between these pairs is not surprising given that the conditions
used to determine and knpt depended on snr. What is unexpected is that the other
parameters involved in these conditions are not correlated. For example, even though
µn also controls N∞, it is not significantly correlated with N∞. Also, no parameters
involved in the second condition for the stability of health or affecting macrophages
directly are significantly correlated with each other.
To further validate the model, we consider our inflammatory phase model with
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Fig. 13. The resulting transients of validation of the model by removal of macrophages
(top) and removal of neutrophils (bottom) are shown. For each, the black,
dashed curve is the representative transient with normal parameters and the
blue curve is the resulting transient when an immune cell population was
removed. The no macrophage data was obtained from [92]. The no neutrophil
data was obtained from [93] and is calculated from cell counts at 24 hours.
both neutrophils and macrophages removed. None of the methods used for the pa-
rameter estimation considered these scenarios, but the model is still able to capture
these dynamics. When macrophages are removed, it has been shown that there is
little change in the peak of neutrophils, but there is delay in resolution for neutrophils
[92]. When neutrophils are removed, macrophage population peaks slightly higher at
a later time, but with no difference in population at 24 hours.
Figure 13 (top) shows how the removal of macrophages affects neutrophils in the
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model and in similar experiments. The black dashed line is the normal response using
the representative parameter set and the blue line is the neutrophil transient when
macrophages are removed (smr = 0). The time course of the response is prolonged
and neutrophil numbers are elevated, which qualitatively matches the experimental
results from Leibovich and Ross [92], top right of Figure 13.
Figure 13 (bottom) shows how the removal of neutrophils affects macrophages.
Again the black dashed curve is the transient from the representative set and the
blue is the resulting transient when neutrophils are removed. The dynamics of the
macrophages are unaffected by the removal neutrophils for about the first 3.5 days
and then the peak of the macrophages is at a slightly higher level and delayed, but
qualitatively the same. This matches the data from Simpson and Ross [93], which
shows no significant difference of macrophages at 24 hours. Although they do not
provide transient data for cell counts in the wound, they do state that the number of
monocytes and their phagocytic activity appeared to be the same in the control and
neutropenic wounds [93].
The removal of macrophages and neutrophils is simulated in all of the 1369
acceptable sets. The changes in the peak times and ranges of the remaining cell
population are given in Table 10. When macrophages are removed, the mean peak
time for neutrophil activity is delayed by 0.31 days and the range is extended. The
minimum remains nearly the same, but the maximum peak time in the population is
delayed by 1.07 days. Macrophage activity peaks early in the absence of neutrophils.
The mean peak time, minimum peak time and maximum time are all earlier by 1.26,
1.36 and 0.89 days, respectively.
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3.7.2 Effects of the Systemic Mediator Estrogen
When Latin Hypercube Sampling of parameter space is performed for each of
the parameters associated with estrogen, we assume that the representative set cor-
responds to experiments with estrogen on (E = 1). In order to simulate the no
estrogen case we adjust the parameters affected by estrogen and then simulate the
model with E = 0. For example, in the representative set kpn has the value 35.03
per N -units/day. We assume this is the rate at which pathogens are destroyed by
neutrophils when estrogen is present, therefore when we model estrogen explicitly and
set E = 1. During sampling, we determine a collection of ken and the other estrogen
parameters, which all give rise to the correct dynamics when estrogen is removed.
This means that ken is set to a value and we solve for kpn. For example, if ken = 2 for
a particular set, then kpn = 11.58 for that set. We do similar calculations for all other
parameters in estrogen effected terms and run our model with these parameters and
E = 0 to determine the no estrogen transients for that particular set.
Using this method and accepting sets that have an increase of the peak on neu-
trophil activity of at least 5% and at most 15% we collected 1,170 acceptable parame-
ter sets. The only notable structural constraints in the resulting distributions for the
estrogen parameters are on the EN∞ distribution. EN∞ ranges between 3.78 and 10,
though sampling allows EN∞ to range between 0.0001 and 10. All other parameters
fill the allowable range used to determine them. Overall statistics for the estrogen
parameters are given in Table 10.
In order to analyze the effect of each parameter on the peak of neutrophils, we
plot points at (ken, EN∞) and color them by the percent increase in the neutrophil
peak when estrogen is removed, Figure 14 (left). This compares the effect of estrogen
on the ability of neutrophils to phagocytize pathogen with its effect on the inhibition
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4.97/E-Units 2.90 0.002 10 [58, 10]
Table 10. Description of the estrogen parameters, mean, standard deviation, mini-
mum, and maximum for resulting sets. The sampling of each parameter is
constrained so that that value is set less than ten.
of the activation of neutrophils. As EN∞ is increased, inhibition by estrogen on
the activation of neutrophils is decreased. Therefore, when estrogen is removed the
change in the peak is less for larger EN∞. As ken is increased, estrogen facilitates
neutrophils phagocytosis more effectively. So when estrogen is removed, the peak
of the neutrophil activity increases as ken increases. The changes in the neutrophil
activity peak are more sensitive to changes in these parameters in the strong inhibition
(EN∞ smaller) and smaller facilitation (ken smaller) region. In the higher ken region
the change in peak levels is mostly due to change in the inhibition parameter.
On the right plot of Figure 14, we plot points at (kem,EM∞) and color them
by the percent increase in the macrophage peak when estrogen is removed. This
allows us to compare the effect of estrogen on ability to facilitate the phagocytosis
of macrophages to its inhibitory effect on the ability of macrophages to self-activate.
Like with the neutrophil associated parameters, as EM∞ is increased, inhibition by
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Fig. 14. The results of estrogen parameters contribution to the percent change in peak
time of neutrophils (left) and macrophages (right) are shown. On the right,
points were plotted at (ken, EN∞) and colored by percent increase in the peak
of neutrophil activity when estrogen is removed. On the left, points were
plotted at (kem, EM∞) and colored by the percent increase in the peak of the
macrophage activity when estrogen is removed.
estrogen on the macrophage self-activation is decreased. However, changes in this
parameter do not significantly affect the peak of macrophages. As kem is increased,
estrogen facilitates macrophage phagocytosis more effectively. So when estrogen is
removed the peak of the macrophage activity increases as kem increases.
To investigate the change in the overall transients as a result of removing estrogen
from the system, we plot the mean of the transient with no estrogen, the transients
from the representative set, and indicate the region contain all no estrogen transients
(gray regions) in Figure 15. The solid line indicates transients of debris and the
inflammatory cell populations from the representative set (with estrogen on, E = 1).
The dashed line is the mean of the resulting set of transients with estrogen removed
(E = 0). As expected, the absence of estrogen increases the peak of neutrophils
and delays the peak, causing a slightly extended inflammatory response. As for
macrophages, there is a significant delay in resolution, if the macrophages return to
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Fig. 15. The change in the transients due to the removal of estrogen is shown. Tran-
sients from the representative set (estrogen on, E = 1) are plotted in black
(solid curve) for debris (left), neutrophils (center), and macrophages (right).
The dashed line is the mean of the transients that resulted from removing
estrogen (E = 0). All resulting sets with E = 0 lie in the gray region. For the
macrophage plot, the darker gray region indicates where most of the resulting
transients lie.
zero. The darker grey band contains most of the transients and those in this band
resolve to the healthy outcome, indicating that a majority of parameter sets lead to
transients that resolve to zero macrophages. The light band contains a few transients
and these lead to unhealthy, inflamed outcome with elevated macrophages. This is due
to the fact that our standard initial conditions are no longer in the basin of attraction
of the healthy outcome. These changes in the inflammatory cell population can give
rise to either faster or delayed removal of debris. The overall effect of removing
estrogen does not change the pathogen transients significantly (not shown).
3.8 Discussion
We derive a model focused on neutrophils and macrophages, the two major cells
types in the inflammatory response during wound healing. Furthermore, this model
accounts for the inclusion of systemic mediators cortisol and estrogen in order to better
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capture the dynamics of the wound healing process. Latin Hypercube Sampling of
parameter space is performed, first on the system without any mediators, and then
individually on the system with the each systemic mediators to determine acceptable
parameter sets for known biological phenomenon.
Latin Hypercube Sampling of parameter spaces for this expanded inflammatory
system is successful at choosing sets of parameters that yield appropriate dynamics
based on the different roles of the different inflammatory cell types. This collection of
parameter sets is representative of a population of individuals with slight differences
in normal wound healing dynamics. This lays the groundwork to establish a patient
specific model of wound healing to predict patient outcome and to provide patient
specific treatment protocols.
In order to create a model that more accurately accounts for differing dynam-
ics with the normal population, the inclusion of systemic mediators is necessary.
Specifically, the inclusion of estrogen in the system allows for gender- and age-based
models that more accurately account the differences in healing of pre-menopausal
females versus males and older females. It is known that the presence of estrogen in
pre-menopausal females leads to a more effective healing response than in males and
post-menopausal females [58, 10, 11] and our model accurately captures this behavior.
The sampling process focuses on changes in the peaks of the inflammatory re-
sponse, but is able to capture many aspects of wound healing process. Simulations of
the inflammatory model without systemic mediators using each parameter set shows
that appropriate dynamics are achieved for each of the inflammatory populations for
the entire set of parameters. Additionally, the model is validated by removing each of
the inflammatory cell populations and comparing these results to experimental data.
Without macrophages, the neutrophil response is lengthened, but pathogen and de-
bris are cleared. Without neutrophils, the macrophage response is more effective and
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shortened due to the lack of oxidative stress caused by neutrophil activity.
Simulations of the model with estrogen on the accepted sets lead to biologically
accurate transients. In the presence of estrogen, neutrophil infiltration and fixed tissue
monocyte differentiation into active macrophages is inhibited [56, 58]. This causes
macrophage response to occur sooner with estrogen on than in those wounds without
estrogen and thus leads to a more effective inflammatory response when estrogen is
present. Also, the phagocytic ability of neutrophils and macrophages is increased
when estrogen is presence, which also contributes to a more effective inflammatory
response to remove pathogens and debris [9, 59].
Our results illustrate that Latin Hypercube Sampling of parameter space is suc-
cessful at capturing these biological dynamics and can be used to account for variation
in population. It remains for the model to be incorporated in the larger model for
wound healing, which includes fibroblast infiltration and collagen deposition and mat-
uration. Additionally, the regulation of wound healing by macrophages that occurs
during the repair phase, and is a hallmark of the M2 type macrophages, will need to
be accounted for in the full model. We anticipate that the full model will allow us
to explore wound dynamics in the population under circumstances of trauma with
differing levels of estrogen based on gender and age. Additionally, a detailed model of
the inflammatory phase allows for future implementation of new treatment strategies
that modulate the inflammatory process. This will be a necessary step to studying
effective treatments of chronic wounds. Chronic wounds typically result from a failure
to resolve the prolonged inflammatory phase of healing and therefore treating these




MATHEMATICAL MODEL OF GAS EXCHANGE IN THE LUNGS
AND BODY
4.1 Introduction
Ventilation induced lung injury (VILI) is a substantial medical issue that harms
patients and challenges physicians. Damage from VILI causes fluid to accumulate in
the capillaries of the lung causing acute respiratory distress syndrome (ARDS), which
makes oxygenation of the surrounding lung tissue difficult and oftentimes impossible
and can cascade into lack of oxygenation of tissues throughout the body. This damage
is exacerbated in elderly patients, who tend to have other diseases and damage to
their lungs when treatment is required. In 2005, 8 thousand hospitalizations required
mechanical ventilation, 4% of which were elderly, high risk patients, and 45% of which
had addition medical conditions [110]. Mathematical modeling of lung ventilation
could aid physicians in making a priori decisions about the need for ventilation in high-
risk patients and save lives. In this chapter, we will discuss the biological background
of the breathing cycle and oxygenation of tissues in the lungs and body and we will
introduce and analyze a modified mathematical model of gas exchange and other
processes involved in the oxygenation.
4.1.1 Biological background
In the lung, a tissue barrier lines the alveolus and separates blood in the capillary
from the air in the alveolus. Oxygen molecules diffuse, or move from an area of high
concentration (the airspace) to an area of lower concentration (the blood in the lung
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capillary). On the otherhand, this tissue in the body requires oxygenation. So when
blood flows near a low-oxygenated tissue, the oxygen molecules diffuse from the blood
into the tissue. Hemoglobin molecules present in the blood of the capillaries bind
oxygen molecules and transport it out of the lungs and into the body. In the body,
the oxygen unbinds from the hemoglobin and diffuses out into the surrounding tissue.
Hemoglobin and oxygen cooperatively bind, which is facilitated by four heme
groups onto which the oxygen attaches. Oxygen-rich hemoglobin, called oxyhe-
moglobin, is classified as unsaturated if all heme groups are lacking oxygen, partially
saturated if one to three heme groups are oxygenated, and fully saturated if all four
heme groups are oxygenated. Each time an oxygen molecule binds to one of the heme
groups, the shape of the molecules chages and its affinity for subsequent binding is
reduced.
Alongside the exchange of oxygen in the capillaries of the body, carbon dioxide
dynamics are occurring at the same time and in the direction opposite relative to
oxygen. In the peripheral body, carbon dioxide diffuses into the blood from the tissue
where it is carried into the lung diffuses from the capillary blood through the tissue
barrier and into the alveolus of the lung. It is subsequently expelled on exhalation.
The presence of water molecules in the blood facilitates the creation of a carbonic
acid molecule, which dissolves in the blood. This dissociation creates a bicarbonate
ion and a hydroxide ion, which can be used to calculate the pH of the blood at a
given location in the body. An increase in the amount carbon dioxide makes the
blood more acidic and a decrease in the amount of carbon dioxide makes the blood
more basic. Thus, changing levels of carbon dioxide in the blood causes changes in
pH of the blood which also affects the dissociation of oxygen, and therefore affects
hemoglobin’s affinity for oxygen. An increase in pH (making the blood more basic)
makes hemoglobin’s affinity for oxygen increase, and a decrease in pH (making the
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Fig. 16. This figure shows graphical representation of the gas exchange process in the
lungs and body. Blood flow is indicated with black arrows and partial pressure
of oxygen and carbon dioxide are indicated in important location throughout
the loop. Interactions between molecules are indicated by arrows.
blood more basic) making hemoglobin’s affinity for oxygen decrease.
We aim to create a mathematical model that focuses on the diffusion of oxygen
and carbon dioxide dynamics over space of a blood capillary in the lungs and body.
Then we will create a loop that accounts for blood exiting the lung to circulate the
body and return to the lung, shown in Figure 17. We modify hemoglobin dynamics
to account for more binding states than the previous model, and discuss a method for
determining pH from carbon dioxide levels and how this is useful for our model. Fur-
ther details will be discussed, in addition to an explanation of existing mathematical
models, including the model on which our new model is based.
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4.1.2 Mathematical background
Many mathematical models of gas exchange have been studied in the past, how-
ever, none of them consider the effects of ventilation associated lung damage with the
inclusion of a model of gas exchange in the body to close the breathing loop [111,
112, 113, 114, 115, 116]. Ben-Tal, 2006 presents the development of a multi-scale
model of gas exchange in the human lung [116]. The author initially models the lung
as a single inflexible compartment, accounting for total pressure averaged over each
alveolus, which accounts only for the fact that the lung can hold air. This simplified
model is then modified to account for the flexibility of the lung by accounting for
the lung as a “container” with a moving plate attached to a spring that causes air to
move in and out. The author introduces variables for the mass, friction, and area of a
plate, along with a spring constant on the spring that moves the plate. The resulting
movement of the plate represents expansion and compression of the lung.
In addition to a model that accounts for basic lung physiology, gas exchange is
introduced into the system. Pulmonary capillaries are accounted for in the model
and blood partial pressures of oxygen and carbon dioxide are also introduced as
parameters. Finally, gas transport is accounted for by allowing for the change in
blood partial pressures of carbon dioxide and oxygen. Blood flow is modeled by
using different containers to account for heartbeat. A large container represents the
input of dissolved gas into the capillary, where it is transported. The main drivers of
transportation of carbon dioxide and oxygen modeled is bicarbonate and hemoglobin,
respectively [116].
Several models exist that explore the pathiophysiology mechanics of certain dis-
eases on lung functionality [117, 118]. Chakraborty et al. (2007) explores hypoxemia
in hepatopulmonary syndrome by creating a multi-scale model of the gas exchange
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process. The model accounts for shunting of the alveolus in a heightened disease state.
Cox et al. (2009) explores lung dynamics in chronic obstructive pulmonary disorder
(COPD). This model explores how airway inflammation caused by the disease effects
a patients lungs and the lungs ability to adequately oxygenate blood.
Computational fluid dynamics can also be useful in lung modeling efforts, where
air is treated as a fluid flowing into the lung. Fluid dynamics can be useful in exploring
the airway remodeling process and inhalation toxicology [119, 120, 121, 122, 123].
These models analyze shear stress/strain of the trachea and alveolus that results
from mechanical ventilation. Pidaparti et al., 2013 explores stress on the alveolar sac
based on airflow and the geometry of the air sac. Two models are considered with
the geometry of the alveolar sac. One model uses data obtained from a scanning
electron microscope, and the second, an idealized version of the alveolus as a sphere.
The model contains fluid and solid dynamics to account for the air in the alveolus
in addition to the tissue that makes up the outer walls. Traditional Navier-Stokes
equations are used to model air flow and equations of motion for sac wall equations.
The simulations of these models are computationally expensive but the results are
physiologically relevant independent of the alveolus shape used in the model.
The model discussed in this chapter, an extension of Reynolds et al., 2010 [13],
relies on PDEs and accounts for spacial and temporal dynamics of gas exchange in
the capillaries. We aim to create a model of these dynamics that can later be used to
account for inflammation in the lung during different disease states and after periods
of mechanical ventilation. In the next section, we present a detailed discussion of
Reynolds et al., 2010 in order to facilitate a discussion of the new mathematical
model.
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4.2 Previous Mathematical Model
The model presented in Reynolds et al. (2010) focuses on modeling gas ex-
change dynamics in the lung across the capillaries that line the alveolus and the
effect of inflammatory stress on these dynamics. The local dynamics of gas exchange
are explored by modeling a respiratory unit (RU) that consists of approximately 25
alveoli and their surrounding capillaries. The compartments modeled include the
alveolar airspace, tissue lining the alveolar airspace, and the capillary. Partial pres-
sures of oxygen (PO2) and carbon dioxide (PCO2) are accounted for, in addition
to hemoglobin dynamics and the bicarbonate buffer system dynamics. Diffusion is
assumed to occur from the airspace to the tissue and from the tissue to the blood, as
well as in the other direction. The tissue and capillary that line an RU are modeled
using a uniform grid, broken down into 20 equally spaced units.
Figure 18 shows a schematic of the variables modeled. The interactions be-
tween these variables along with inflammation involvement included in the system is
depicted. Inflammatory pathways and inflammatory cell populations will not be ex-
plicitly accounted for in our model. It is our intention to create a model that sets the
framework for breathing using a closed loop, such that the values of the blood vari-
ables exiting the lung are linked to their levels as they enter the lungs. In Figure 18,
the white/green arrows represent the binding and unbinding of oxygen to hemoglobin
and blue/white arrows represent the dissociation of carbon dioxide into bicarbonate.
These processes are the main drivers of gas exchange in the body and typically occur
in one direction in the lung, where oxygen is moving in from the airspace and carbon
dioxide is moving out into the airspace [13]. A more detailed explanation of the vari-
ables and their dynamics are discussed in the next section, where we introduce the
partial differential equations model of the gas exchange in the lung.
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Fig. 17. The model schematic for a single RU is shown. Inflammation is indicated
in this schematic as N0, NA, NAB, and TNF . Further discussion of these
dynamics, which are omitted for our purposes, can be seen in [13]. Figure 1
from [13] reprinted with permission.
4.2.1 Oxygen Dynamics in the Lung
Reynolds et al. (2010) begins by modeling partial pressure of oxygen in the
alveolus (PO2A), blood (PO2Bi), and tissue (PO2T i) for each spacial unit i. The
equations include diffusion-type terms to account for movement between the alveolar,
blood, and tissue compartments of oxygen and carbon dioxide. Diffusion is modeled in
the traditional sense but with the diffusion from the tissue into the airspace depending
on the sum of the partial pressure over all spacial units in the tissue. This accounts
for the well mixing of the air in the alveolus. Equations (4.1)-(4.3) model diffusion
between compartments where DO2TB and D
O2
TA represent the rate of diffusion of oxygen
between tissue/blood and tissue/alveolus, respectively. The parameters VB0, VT0, and





A scale the molar concentration to partial pressuresof oxygen in the blood,
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DO2TB(PO2Bi − PO2T i)
σO2T VT0
+










(PO2T i − PO2A) (4.3)
Hemoglobin and oxygen dynamics are modeled in the blood by Equations (4.4)-
(4.6). In this model, hemoglobin dynamics are simplified so that there exists two
states: partially saturated hemoglobin with m = 0.4 oxygen bound, and fully satu-
rated hemoglobin with m = 4 oxygen bound. Partially saturated hemoglobin. Hbm
requires 4 − 3.6 oxygen molecules bind to form HB4 at a rate of k+ and detaches
from HB4 to form HBm at a rate of k
−. The number of oxygen units needed to go
between these two states was determined so that the overall hemoglobin saturation
is appropriate at moderate and high PO2 levels.
dHBm
dt












The constant THB indicates the total amount of hemoglobin in the system. Here,
HBm = THB−HB4 since total hemoglobin in the body is conserved. Equations (4.7)-
(4.8) give the final form of the oxygen dynamics in the blood where the final terms
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DO2TB(PO2T i − PO2Bi)
σO2B VB0
+m






= k+(THB −HB4)POm2B − k−HB4 − v∇iHB4i (4.8)
In order to model the spatial dynamics of oxygen in the tissue component of
the model, we must account for diffusion between the units in this compartment in
addition to the diffusion dynamics into and out of the tissue compartment already
discussed. To do so, we use the second order centered discretization approximation
∇2i for the second derivative, where dynamics in unit i depends on dynamics in units




DO2TB(PO2Bi − PO2T i)
σO2T VT0
+
DO2TA(PO2A − PO2T i)
σO2T VT0
+DCT∇2iPCO2T i (4.9)
Aside from the oxygen dynamics in the blood and tissue, we must also modify
alveolar oxygen dynamics, Equation (4.3) in order to account for the breath cycle. We
use the smooth Heaviside function, described in Chapter 2.2.2 and given in Equation
(4.10). We also use an inhalation:exhalation ratio of 1:3 with the parameters VC0
representing alveolar ventilation, the air volume taken in during one breath cycle,
and the parameter VAmin0 representing residual volume, the volume left in the lung
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after exhalation, on an RU. We first derive equations for the change in alveolar volume
on an RU, Equations (4.11)-(4.12) with parameters τ1 and τ2 set so that in tin = 1s
the function y reaches VC0 and decays to zero in tout = 3s. Therefore, the sum of











VA0(y) = VAmin0 + y (4.12)
These volumes are used to account for changes in alveolar partial pressure of
oxygen (PO2A) during a breath cycle. Similar to diffusion, we must convert the
number of oxygen molecules to partial pressure of oxygen. The term VA0[O2] calculates
the number of oxygen molecules and therefore Equation (4.13) models the change in
molecules do to inhaltion rather than diffusion. Equation (4.14) is derived by using
the product rule and assuming that the air oxygen concentration is constant. Dividing
this equation through by σA yields the equation for PO2A, given in Equation (4.16).
The last equation represents change in PO2A only during inhalation and thus, the




















PO2A = R(PO2air − PO2A) (4.16)
The final equations to account for oxygen dynamics in the lung are given in
Equations (4.17)-(4.20). For further explanation and discussion of the derivation of
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4.2.2 Carbon Dioxide Dynamics in the Lung
Carbon dioxide dynamics are modeled similarly to oxygen dynamics but ac-
counting for the use of the bicarbonate buffer system. Transport of carbon dioxide in
the body relies in the presence of water molecules in order to dissociate the carbon
dioxide as bicarbonate. These dynamics are modeled using Michaelis-Menten type
terms representing the catalytic reactions between the carbonic acid and bicarbonate
substrates. The parameters kcatCB and kcatHC represent the maximum rate of the
catalytic reactions with CO2 and HCO
−
3 as the substrate, respectively, and the pa-
rameters kmCB and kmHC are the Michaelis-Menten constants for the reactions. The
parameters σCB and σ
C
T scale the concentration of carbon dioxide in the blood and
tissue, similar to the σO2B and σ
O2
T constants for oxygen. The discretized equations for

































To finalize the carbon dioxide subsystem, we mimic the derivation of PO2T and
PO2A to create Equations (4.23)-(4.24). The parameter D
C
TA is the diffusion rate
from tissue to air of carbon dioxide and the constant σCA scales concentration to
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(PCO2T i − PCO2A) (4.24)
+

Inspiration R(PCO2air − PCO2A)
Expiration 0
Collectively, Equations (4.21)-(4.24) model dynamics of carbon dioxide in the
lung. These equations model the dynamics on each RU of the lung, however variability
of blood and tidal volume exists throughout the lung, which will be discussed in the
next section. Further discussion of the derivation of these terms can be found in [13].
4.3 New Model Development
We begin our modeling efforts with the equations described in the previous sec-
tion. To start, we modify the model to include two new waveforms for normal and
mechanical ventilation. The normal ventilation waveform will allow for the uptake of
700mL of air into the alveolar space with inhalation and exhalation times of 1.33 sec-
onds and 2.67 seconds, respectively. The mechanical ventilation waveform will allow
for the uptake of 450mL if air with inhalation and exhalation times of 0.66 seconds
and 1.33 seconds, respectively. These new waveforms are essential parts for the model
in order to later account for the inclusion of lung inflammation when a ventilator is
used. The normal breathing waveform will serve as a baseline on which to analyze
the results of the mechanical ventilation model.
The next adaptation of the existing model is to include three hemoglobin bind-
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ing states. Non-saturated, partially saturated, and fully saturated states will be
accounted for, as opposed to only two in the previous model, which did not explic-
itly include a zero saturated hemoglobin state. This modification will ensure that
we have a more accurate model of oxygen in the body during several disease and a
more biologically relevant model of ventilation that could be created by extending
this model to include the binding of carbon dioxide to heme groups in later modeling
efforts. In addition, we close the breathing loop of the model to allow for the input
of the lung model to be the output of the body model. To do so, we create a small
length of capillary where blood leaving individual RUs of the lung can mix together.
This creates a way to account for different amounts of blood and oxygen in individual
RUs, depending upon the location of the RU in the lung, allowing for the variability
in oxygen concentration leaving the lung. After the blood mixes, it enters the body
where the gas exchange process continues. Oxygen molecules in the blood will de-
tatch from the hemoglobin and diffuse from the blood into the tissue. On the other
hand, carbon dioxide will move into the blood from the surrounding tissue, where it
will be returned to the lung.
Since there is no additional compartment involved in the gas exchange process in
the body, we account only for dynamics of blood movement through the capillary and
the diffusion of gasses into and out of the tissues in close proximity to the capillary.
Figure 19 illustrates the dynamics of blood moving through a body capillary, into
and out of the tissue located close to the capillary, and then into and out of the tissue
that is some distance away from the surrounding tissue.
4.3.1 Breathing and Mechanical Ventilation Waveforms
The new waveform for normal breathing has the inhalation of 700 mL of air
over one breath cycle (four seconds) is modeled by a sinusoidal equation. Sm is
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Fig. 18. Model schematic for gas exchange in the body. Interaction of Oxygen with
Hemoglobin and Carbon Dioxide with Bicarbonate are shown. In addition,
the diffusion of the gases from the blood to the tissue is indicated by arrows
in the direction they diffusion is expected to occur.
a smooth approximation to the Heaviside function, similar to the one used in the
previous section. In this case tin = 1.33 (inhalation time), tout = 2.67 (exhalation
time) seconds, with ttot = tin+ tout, and the Heaviside function causes there to be two
different function definitions for inhalation and exhalation. Specifically, Equations
(4.25) and (4.26) show the functions for inhalation and exhalation, respectively, and


















( mod (t, ttot) + 1.34)
)
(1− Sm(tin − mod (t, tin + tout))
(4.26)
The new waveform for ventilation with inhalation of 450mL of air over one breath
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cycle (two seconds) is modeled by a constant function for inhalation and an expo-
nential function for exhalation. In this case, inhalation and exhalation occur for
tin = 0.4 and tout = 1.6 seconds. More specifically, Equations (4.26) and (4.27) show
the function for inhalation and exhalation, respectively (bottom of Figure 20).
Kin = 1050Sm mod(t, ttot) (4.27)
Kout = 428.49e
(−2.45 mod(t,ttot)+0.98)(1− Sm) (4.28)
4.3.2 Modeling Hemoglobin and Oxygen in the Lung
As described before, oxygen reacts with hemoglobin in the blood of the lung
compartment and attaches to heme groups in order to be carried out of the lung
and into the capillaries of the body where it detaches in order to diffuse out and
oxygenate the tissues of the body. Hemoglobin with no binding sites filled (Hb0),
partially saturated (Hbm), and saturated hemoglobin (Hb4) are modeled. We refer
to Hb0 and zero-saturated hemoglobin, Hbm as unsaturated hemoglobin, and Hb4
as saturated hemoglobin. Oxygen binds to Hb0 to form Hbm at the rate k
+
0 and it
detaches at the rate k−0 . Similarly, oxygen binds to Hbm to form Hb4 at the rate
k+m and it detaches at the rate k
+
m. The reaction dynamics are outlined in Equations
(4.29) and (4.30). In the blood, the parameters are related to each other such that
k+0 < k
+
m to account for the previously discussed dynamics of hemoglobin’s affinity
for oxygen.
Hb0 +mO2 ⇀↽ Hbm (4.29)
Hbm + (4−m)O2 ⇀↽ Hb4 (4.30)
The equations governing these dynamics, created based on tradition reaction
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Waveforms for Normal Breathing and Mechanical Ventilation
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Fig. 19. The waveforms for normal breathing (top) and ventilation breathing (bottom)
are shown. The normal ventilation waveform has 1.33 second of inhalation and
2.67 seconds of exhalation while the ventilation waveform has 0.67 seconds of
inhalation and 1.33 seconds of exhalation.
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0 Hbm − k+0 Hb0POm2 (4.31)
d
dt



















Total concentration of hemoglobin, THB is conserved, so THB = Hb0 +Hbm+Hb4

























In this model, the value of the parameter m determines how many oxygen
molecules must be bound to zero-saturated hemoglobin in order for it to be partially
saturated, and subsequently, 4−m oxygen molecules must bind to partially saturated
hemoglobin in order for it to be fully saturated. We assume Quasi-steady state for









m constant for the chosen values of m. We use hemoglobin saturation






. Any value of the parameter between m = 1.7
and m = 3.6 lead to physiologically relevant oxygen exchange dynamics, so we chose
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the value m = 2.1.








m are determined using
the desired m-value. The optimal values for these ratios is determined by Equations
(4.38) and (4.39). Hemoglobin saturation percents (Sh) for partial pressure of oxygen
(PO2) levels is known. Thus, we use the points (PO2, Sh) on the hemoglobin satura-
tion curve, (0, 0), (80, 0.9), and (50, 0.7), to derive these equations. We then simplify
these equations based on the quasi-steady state of saturation of bound hemoglobin.
RH0 = 0.40e
4.38mm− 0.90e3.91mm− 0.16e4.38m + 1.04e3.91m (4.38)
RHm =
2.36108
35e4.38mm− 45e3.91mm− 14e4.38m + 54e3.91m
(4.39)
We then fit the values for the k+x parameters based on the known relationship
k+0 < k
+
m to account for oxygen affinity to hemoglobin based on the number of oxygen
molecules already bound. Once this values is chosen, we include the blood flow as spa-
tial dynamics in the model, as described before and given in Equations (4.40)-(4.42).
We then discretize the spacial dynamics where ∇i is the discrete approximation of
83
the first derivative. The discretized form is shown in Equations (4.43)-(4.45).
d
dt
Hbm = −k−0 Hbm + k+0 (THB −Hbm −Hb4)POm2 (4.40)































Hbm = −k−0 Hbm + k+0 (THB −Hbm −Hb4)POm2 (4.43)





Hb4 = −k−mHb4 + k+mHbmPO
(4−m)













We use these equations to model oxygen and hemoglobin dynamics that account
for the added hemoglobin state. Equations (4.46)-(4.50) show the final form of the




Hbm = −k−0 Hbm + k+0 (THB −Hbm −Hb4)POm2 (4.46)





Hb4 = −k−mHb4 + k+mHbmPO
(4−m)
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(PO2T i − PO2A)
+

Inspiration R(PO2air − PO2A)
Expiration 0
(4.50)
4.3.3 Modeling Blood pH and Carbon Dioxide in the Lung
The carbonic acid buffer system in the blood, reactions shown in Equation (4.51),
is the main driver of blood pH, as previously discussed. The value for pH is typically
calculated by taking a negative logarithm of the molar concentration of hydroxide
ions in a liquid. Experimentally, pH in the blood is easy to measure, so we added it
to this model to facilitate parameter fitting once the inflammatory effects are added.
H+ +HCO−3 ⇀↽ H2CO3 ⇀↽ H2O + CO2 (4.51)
If inflammation is causing pathological blood conditions when blood is in the
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lung, the level of carbon dioxide may be elevated, and accounting for blood pH could
add a additional level of complexity in the system to help with future analysis. We
use existing variables to create a way to explicitly calculate the pH of blood at a
given spatial unit in Equation (4.52). The derivation of this equation can be found in
literature where [HCO−3 ] is the concentration of bicarbonate in the blood in mmol/L,
PO2 is the partial pressure of carbon dioxide in the blood (in mmHg), kCO2 is the
solubility of carbon dixoide and pK ′ is the pK of the HCO−3 − CO2 system in the
blood. The values of these are given in literature as kCO2 = .03 and pK
′ = 6.1.






This equation can be used to calculate pH of the blood in the lung or body, once
the closed loop breathing model is completed. We do not alter the carbon dioxide
dynamics from the previous model, given in Equations (4.21)-(4.24).
4.3.4 Closed Loop Breathing
4.3.4.1 Well Mixing
We require a closed loop breathing model in order to account for the effect of
accumulated inflammation over multiple breath cycles. The use of RUs in the lung
allows for a more accurate representation of differing oxygen levels in different areas
of the lung and in order to properly model the well mixing of this blood as it exits
the lung, we include a well mixing compartment in the model that is ten spacial units
in length. Different alveolar regions of the lung are defined by the amount of tidal
volume of the lung (Vc), the amount of air in the lung (Vt) and the amount of blood
in the capillary (Vb). This is illustrated in Figure 21.
The equations for the well-mixing compartment have the same form as the blood
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equations in the lung with the diffusion terms between tissue and blood omitted. All
other alveolar and tissue compartment dynamics are excluded and only the inter-
actions between HBm, Hb4, PO2, HCO
−
3 , and PCO2 are modeled. The equations
governing these dynamics are given in Equations (4.58)-(4.65).
d
dt
Hbm = −k−0 Hbm + k+0 (THB −Hbm −Hb4)POm2 (4.53)





Hb4 = −k−mHb4 + k+mHbmPO
(4−m)











































4.3.4.2 Gas Exchange in the Body
We model gas exchange in the body similar to gas exchange in the lung with the
exclusion of alveolar oxygen and carbon dioxide. Since there is no alveolar air space,
no waveform, breathing variable, or equation of alveolar oxygen and carbon dioxide
are required. The model accounts only for partial pressures of oxygen and carbon
dioxide in the blood (PO2B/PCO2B) and the tissue (PO2T/PCO2T ). It also accounts
for the three states of hemoglobin, Hb0, Hbm, and Hb4, as described in Chapter 4.3.2.
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Fig. 20. The relative position of the lungs and body, as represented in this model.
Prior to entering the body, well-mixing of variables in this model occur [13].
Modified with permission.
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We use the same value of the parameter m for how many oxygen molecules my bind
to zero-saturate hemoglobin in order for form partially saturated hemoglobin. In
addition, we use the same dynamics for the bicarbonate buffer system and model
carbon dioxide dynamics with bicarbonate the same as before. The equations and
parameters governing gas exchange in the body will be the same as those derived in
the lung model.
The code for the calculation of body blood and tissue volumes is given in Ap-
pendix C3.1. We assume that the entire blood volume is 5L and that the blood
volume in the lung is 0.9L. We determine the relative size of the tissue compartment
in the body by assuming that the blood unit has a set radius and that we are only
modeling the body tissue within that radius from the blood. We then include the
terms −µO2T iPO2T i and +µCO2T iPCO2T i in the equations to account for the loss of
oxygen to and uptake of carbon dioxide from the surrounding tissue that is not ex-
plicitly accounted for in the model. The form of this term is a simple decay depending
upon the amount of oxygen and carbon dioxide in the tissue. The discretized final
model of body dynamics is given in Equations (4.58)-(4.65). Appendix C3.2 shows
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2 − v∇iHBm (4.60)
dHb4i
dt
= −k−mHb4 + k+mHbmPO
(4−m)










































4.3.4.3 Blood and Tidal Volume Variation
We also desire the ability to run analysis with well mixing over many instances
of Vt/Vb combinations. One useful way to create the alveolar regions is to gather a
distribution and divide individual intervals, Vt ∈ [135, 1050] for example, into smaller
intervals, one of which could be V ′t = [695, 705]. Any value of the distribution chosen
for the tidal volume that falls within that interval is weighted in the well mixing
compartment as the center of the subinterval, V ′t = 700 in the previous case. This is
called “binning” the distribution and allows use to reduce the computation time of
the model significantly. The results of the “binned” well mixing is then fed into the
body.
Appendix C3.3 shows the code that can perform this distribution where the user
inputs the desired number of simulations, which will be divided up among the bins of
desired length, and the desired range of the distribution. A weight vector is returned
that the user could then apply to a lung code where the user would be responsible
for ensuring that there are enough spacial units and locations in the body to be
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able to accept the number of bins chosen. The computing power required by this
is substantial, so we encourage future generations to perform these techniques when
computers become even more powerful.
In order to avoid massive computation times, we choose three representative
values of Vt/Vb combinations and simulate breathing in well mixing and use the output
as an input to the model of gas exchange in the body. Specifically, three main tidal
and blood variations were used which represent high and low extremes as well as a
mid-range choice. That is, we use the combinations Vt = 700/Vb = 90 to represent
mid-range blood and tidal volumes, and Vt = 350/Vb = 45 and Vt = 1050/Vb = 135
to represent the extremes.
When fitting the model for oxygen dynamics, we use the mid-range values and
aim to have hemoglobin saturate in the first third of the capillary, and we aim for
the desired PO2 levels leaving and entering the lung. Entering the body (leaving the
lung), we desire a high value for PO2, oscillating within 100-105mmHG, and leaving
the body (entering the lung), we desire a low value for PO2, oscillating within 42-
48mmHG. Afterwards, we simulate the same situation with the ventilation waveform
and expect similar results. When fitting the model for carbon dioxide dynamics, we
aim to mimic those dynamics seen in the previous model, saturation in the first tenth
of the capillary. In the next section, we discuss the results of simulations of the model.
4.4 Results
Closed loop breathing under normal ventilation is shown in Figure 18. Hemoglobin
saturation in the case of Vt = 700 and Vb = 90 is shown (top) with the well mixing
and body dynamics (middle and bottom, respectively) are given. Blood oxygen levels
in the lung are similar for each of the cases, where Vt = 350/Vb = 45 lead to a higher
partial pressure and Vt = 1050/Vb = 135 led to a lower partial pressure of oxygen.
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This is intuitive because a larger amount of blood to oxygenate will take a longer time
to oxygenate regardless of the tidal volume because the same amount of air is touch-
ing and diffusing through the tissue. On the other hand, when lung tidal volume and
lung blood volume are decreased Vt = 250 and Vb = 45, hemoglobin saturation occurs
much more quickly and blood levels in the lung are increased. When these dynamics
are mixed with the elevated volumes and implemented into the model in the presence
of inflammation, we expect to see reduced tidal and blood volumes due to swelling in
the tissue. At first, this will cause oxygenation of the blood to occur more quickly,
but the lack of blood being oxygenated at any given time will eventually lead to less
oxygenation of tissue in the body and subsequent low oxygen levels entering back into
the lung. Carbon dioxide dynamics are fit in a similar way where the output of the
lung feeds into a well mixing compartment where carbon dioxide and bicarbonate in
the blood combines from different parts in the lung, and the elevated carbon dioxide
output of the body feeds into the lung on the next breath cycle.
Carbon dioxide has similar saturation dynamics as the previous model with closed
loop breathing cause the carbon dioxide levels to enter slightly higher than they did
before. Figure 22 shows carbon dioxide dynamics in the lung in the case of Vt = 700
and Vb = 90 (top) corresponding to body dynamics in which levels increase as carbon
dioxide is picked up through the body capillary (not shown). There is not much
variation in the value of carbon dioxide in the lung, thus the tenth unit of well
mixing ends up being a constant. It is theorized that, because only two varibles are
interacting in the blood of the well mixing compartment, they dynamics are more
simplified than those seen with oxygen. For the normal breathing waveform, the
constant value obtained in the well-mixing compartment was PCO2b = 43.3mmHg,
as seen as the input of the body model, and the out put of the body model was
PCO2B = 44.65mmHg. Uptake of carbon dioxide in the body is relatively steady, as
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seen in the third panel of Figure 22.
When the parameters chosen for normal breathing are implemented using the
waveform for ventilation, we see similar dynamics in oxygenation of the blood of
the lungs and body, however, the hemoglobin saturation in the lung is occurring at
a slightly reduced rate, within the first fifth of the capillary, shown in Figure 23.
Ventilator breathing caused slightly more effective reduction in carbon dioxide levels
in the lung before entering into the body, shown in Figure 24. The tenth unit of the
well-mixing compartment yeilds the value PCO2B = 43.3, which is input into the
body model and the output of the body model is PCO2B = 43.6, which is input into
the lung model.
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Fig. 21. Gas exchange dynamics in the lungs and body are shown under normal breath-
ing. The top panel shows hemoglobin saturation in the lung with Vt = 70, and
Vb = 90, the middle panel shows well mixing of blood leaving the lung, and
the bottom panel show oxygen levels in the body over time. The hemoglobin
saturations and lung oxygen levels are similar for each combination of blood
and tidal volume.
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Fig. 22. Gas exchange dynamics in the lungs and body are shown under normal breath-
ing. In the lung, carbon dioxide is oscillating around 43.5mmHg. Carbon
dioxide is expelled from the lung within the first unit of space (second panel),
and the body removes carbon dioxide from the surrounding tissue at a rela-
tively constant rate.
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Fig. 23. Gas exchange dynamics in the lungs and body are shown under ventilator
breathing. The top panel shows hemoglobin saturation in the lung with
Vt = 70, and Vb = 90, the middle panel shows well mixing of blood leav-
ing the lung, and the bottom panel show oxygen levels in the body over time.
The hemoglobin saturations and lung oxygen levels are similar for each com-
bination of blood and tidal volume.
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Fig. 24. Gas exchange dynamics in the lungs and body are shown under ventilator
breathing. The results of this simulation are similar, but slightly reduced, to
the results of carbon dioxide in normal breathing.
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4.5 Discussion
We created a mathematical model of gas exchange in the lungs and body that
accounts for multiple binding states of hemoglobin and several different instances
of tidal and blood volume in the lung. In order to improve upon past modeling
efforts, we created two breathing waveforms that account for normal breathing and
ventilation breathing, which allowed for the inhaltion of 750mL and 500mL of air,
respectively. The new waveforms cause smaller variation in the gas dynamics in the
model, and therefore change the overall dynamics slightly. In the lung, for oxygen
and carbon dioxide, we see stabilatization of dynamics at an earlier time point in the
new model than we saw in the previous model. If the mesh of the spatial variable
was further refiend, analysis of these results could be performed and this could lend
to futher understanding of how the dyanamics are changing closer to the beginning
of the lung.
The model in its current state sets the stage for future modeling efforts. To
start, future modeling could include a more in-depth analysis of the effect of blood
pH on the system in the presence of increased inflammation in the lung. In so doing,
the inflammatory response can be accounted for under variations of tidal and blood
volume. We expect an increase in inflammation to initially decrease the blood supply
in the capillary, which at first would cause oxygen saturation to occur more quickly
since less blood, means less oxygenation required to fully saturate. However, in
time, this decrease in blood volume and compromised diffusion is expected to become
detrimental.
Also, once computing powers increase, the distribution of tidal and blood volumes
can be expanded to create a well-mixing of blood that more accurately models a
healthy lung. The effect of mechanical ventilation under different waveforms can
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be explored further, as well, in order to determine what inhalation and exhalation
volumes are most efficient without causing damage that cannot be recovered from.
We created a closed loop allows for three different alveolar tidal volume and
blood volume in the lung to mix before entering the body where peripheral tissue
oxygen levels are maintained and carbon dioxide is removed in healthy patients with
both the ventilator and normal breathing waveforms. In the lung, oxygen dynamics
match that of previous models, where hemoglobin saturation occurs within the first
third of the capillary. In it’s current state, the model sets the baseline dynamics for
including inflammation in the lung and analyzing the effect of tissue swelling after
multiple breathe cycles. While inflammation is not explicitly modeled, including it is
possible.
Along with the ability to relate the partial pressure of oxygen to hemoglobin
dynamics in the body, another clinical application of the model is pH. The measur-
ing of pH of blood is a non-invasive test that can easily be performed, and using
the functionality of this model, we can make predictions about future gas exchange
dynamics in mechanical ventilation. In addition to the ability to make predictions
based on lung dynamics, the inclusion of a body part of this model to close the loop
of breathing allows for the analysis of the effects of inflammation over multiple breath
cycles. Therefore, we conclude that this model is a good first step in the efforts of





We developed several mathematical models to describe various processes in the human
body related to inflammation and wound healing. First, we modeled the process of
hematopoiesis in non-diseased and diseased donors undergoing Filgrstim and Plerix-
afor treatments. We statistically sampled parameters in order to obtain a population
of diseased patients and to explore the effect of Filgrastim and Plerixafor on these pa-
tients. This model can be used further to explore timing of Filgrastim administration
and to identify patients that would benefit from early intervention with Plerixafor
rather than have to restart stem cell collection in the rescue situation. This model
can also be extended to account for a specific chemotherapy and radiation treatment.
In addition, the transplantation phase can be modeled in which the initial condition of
the model are set to biological levels representing a patient after stem cells have been
removed and chemotherapy has been performed. The underlying dynamics may need
altering to account for the repopulation of peripheral stem cells pool in the spleen
and lymph nodes. Comparisons can be done based on differing biological dynamics
and drug effectiveness in the process to model other disease states.
Next, we modeled the inclusion of two immune cell populations in the wound
healing response in addition to the effect of the systemic mediator estrogen on this
process. The model can be extended to account for the remainder of the wound
healing process, the accumulation of collagen in the presence of fibroblasts and how
the presence of systemic mediators effect this process. Wound healing models that
account for the difference in gender could later be used to look at diabetic ulcers and
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wound healing post trauma.
Last, we modeled gas exchange in a closed loop by accounting for well mixing of
the blood leaving different parts of the lung, and gas exchange dynamics in the body.
Two waveforms were implemented in three different tidal volume circumstances. The
inflammatory response can be included in this model of closed loop breathing so the
effect of its presence in the lung can be studied over time. In addition, the well
mixing compartment of the lung can be altered so that a distribution of lung and
blood volumes can feed into this compartment in order to model a more biologically
accurate lung.
Mathematical modeling of physiological processes is useful in the medical fields
as it can help doctors and professionals gain insight into the underlying dynamics of
a disease. Expansion and further development of the models presented here could
lead to models that cal help physicians chose an optimal treatment.
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Appendix A
PATIENT DATA USED TO FIT THE MATHEMATICAL MODEL
HEMATOPOIETIC BONE MARROW STEM CELLS
This Appendix shows patient data used in parameter fitting for the mathematical
model of hematopoietic bone marrow stem cells. Data was collected at the Virginia
Commonwealth University Medical College of Virginia in patients undergoing stem
cell collection and/or treatment at the Massey Cancer Center.
A.1 Blood cell count data for donor patients treated with Filgrastim
Patient Day 1 Day 2 Day 3 Day 4 Total cells collected




4310102 73.24090909 216.15 289.3909091
4323631 302.4454545 384.8454545 687.2909091
4324684 130.4545455 384.3636364 514.8181818
4324799 114.0363636 462.5454545 576.5818182
4331005 161.1 379.8 540.9
4333239 523.8863636 334.6818182 858.5681818
4338440 401.8636364 703.5 1105.363636
4358957 549.4 88.70909091 638.1090909
4359957 214.6909091 133.2363636 347.9272727
4380355 695.7954545 541.5681818 1237.363636
5381996 148.2545455 581.2363636 729.4909091
6076532 583.6363636 650.7545455 1234.390909
4346288 77.07272727 131.3090909 124.8863636 333.2681818
4353937 80.32727273 264.0545455 387.1090909 731.4909091
4393216 270 285 145 700
4341190 106.91 159.27 171.64 86.55 524.36
4378512 131.56 154.15 125.67 84.44 495.82
Average 365.5243182 344.4219251 190.8609091 85.49090909 714.5472727








G-CSF Granulocyte-Colony Stimulating Factor
C Hematopoietic Stem Cell Variable
P Chapter 2-Peripheral Blood Stem Cell Variable
P Chapter 3-Pathogen Variable
Lc Committed Platelet Variable
Rc Committed Red Blood Cell Variable
Nc Committed Immune Cell Variable
Lm Mature Platelet Variable
Rm Mature Red Blood Cell Variable
Nm Mature Immune Cell Variable
L Platelet Variable
R Red Blood Cell Variable
N Chapter 1-Immune Cell Variables
N Chapter 2-Neutrophil Variable
Df Filgrastim Drug Effectiveness Variable
Dp Plerixafor Drug Effectiveness Variable
M Macrophage Variable
Pt Platelet Variable
PO2t Partial Pressure of Oxygen in the Tissue
PO2b Partial Pressure of Oxygen in the Blood
PCO2t Partial Pressure of Carbon Dioxide in the Tissue
PCO2b Partial Pressure of Carbon Dioxide in the Blood
Hb0 Concentration of Zero-Saturated Hemoglobin
Hbm Concentration of Partially-Saturated Hemoglobin
Hb4 Concentration of Fully-Saturated Hemoglobin




C.1 Mathematical Model of Hematopoiesis
• Mathematical Model of Steady State of Hematopoiesis
function system=stemcellsystem8_ss(t,x,U,D)
%This function is the steady state function for the Stem Cell system.
%Open the file for variables and parameter names and their index.


































%% Parameters and Variables for ALL the models, not just the
% steady state model


















































• Mathematical Model of Drug Treatment in Hematopoiesis
function system=stemcellsystem8_dt(t,x,U,D)
%This function is the drug treatment (filgrastim and
plerixafor) function
%for the Stem Cell system. Open tte file for variables
and parameter names
%and their index. This file should be run from the
corresponding run file:
% run8_dt().
%Loading a workspace with correct parameter values
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• Mathematical Model of Removal in Hematopoiesis
function system=stemcellsystem8_r(t,x,U,D)
%This function is the drug treatment (filgrastim and plerixafor)
%function for the Stem Cell system. Open tte file for variables and
%parameter names and their index. This file should be run from
%the corresponding run file: run8_dt().
%Loading a workspace with correct parameter values





































%This function is the drug treatment (filgrastim and plerixafor)
%function for the Stem Cell system. Open the _ss file for variables
%and parameter names and their index. This file should be run
%from the corresponding run file: run8_dt().





























C.2 Mathematical Model of the Inflammatory Response
function dydt = RHS_subsystem_27p(t,y,parameters)
%The RHS of the inflammatory response used for parameter sampling
kpg = parameters(1);kptn = parameters(2);kptm = parameters(3);
nai = parameters(4);Ca = parameters(5);Cinf = parameters(6);
mupt = parameters(7);pinf = parameters(8);kpb = parameters(9);
sb = parameters(10);
mub = parameters(11);kbp = parameters(12);kpn = parameters(13);
kpm = parameters(14);snr = parameters(15);knp = parameters(16);
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knpt = parameters(17); munr = parameters(18);mun = parameters(19);
mum = parameters(20);
knm = parameters(21);smr = parameters(22);kmp = parameters(23);









dN = snr*R1(y(2), y(1), knp, knpt, 1, Ca, Cinf,2)/(munr+R1(y(2), y(1), ...
knp, knpt,1, Ca, Cinf,2))-mun*y(3)-knm*y(4)*y(3)*inhib_f(y(3),nai,2);
%Macrophage Equation
dM = smr*R2(y(2), y(4), y(3), y(1), kmp, kmm, kmn, 1, kmpt, Ca, Cinf,2)/...
(mumr+R2(y(2), y(4), y(3), y(1), kmp, kmm, kmn, 1, kmpt, Ca, Cinf,2) )...
+-mum*y(4);
dydt = [dPt; dP; dN; dM];
C.3 Mathematical Model of Closed Loop Breathing
C.3.1 Calculation of Blood and Tissue Volumes in the Body
function [h,vb0_div,vb0_tot,vt0_tot] = calc_vols(n,m,blv,s)
% Choose n = desired number of spatial units of capillary,
% m = desired total length of capillary,
% blv = desired volume of blood in lung, (0.9 in previous model) -- ((may end
% up being a function of time later))
% s = (function) length of tissue between the end of the blood vessel and
%the end of the tissue relative to the radius of the tissue
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% Output:
% h = grid size
% r = radius of capillary









C.3.2 Mathematical Model of Closed Loop Breathing









• Mathematical Model of Closed Loop Breathing
function r = dx_lung_o2(t,X,data1,data2,data3)
r=zeros(81,1);















% Gas levels in the air that is being inhaled and speed of blood
gair0=104;v0=0.018;v=v0;
% Alveolus count and scaling
auc=0.12e8;auc_L=auc*1000;
% Waveform; integrated equation representation
WF_flag=0;
































































%% Lung Carbon Dioxide














































% DE for unsaturated hemoglobin in the well mixing compartment








% DE for saturated hemoglobin in the well mixing compartment

























































































C.3.3 Calculating Distributions for Tissue and Blood Volumes
function [count_matrix,tbv_pairs,Y,Z] = Create_countmatrix_final(tot_random_num)
%This code creates a matrix of the bins that will be used for running the
%lung code for different size air and blood compartments. The intervals for
%air volume are [345,355],[355,365], etc with the middle of the interval
%being the number that is run in the code. This is similar for blood
%volumes, as [28,32],[32,36],... with the middle of the interval being the
%number that is run in the code.
%
%This code also creats the random vectors and calulates how many pairs
%exist in the bins we have created. This should only need to be done once
%and the final vector used forever, but this will repeat the process each
%time. We make it easy to ensure that you end up with the total number of
%random samples that you want.
%
%Always run this code with the file ’’Dist_for_air_and_blood_vols.mat’ in
%the same directory. This ensures that you do not need the statistics
%toolbox with your Matlab instillation in order for the code to work.
%
%tot_random_numbers should be set equal to the number of random numbers you


















































error(’Error. \n Something is not right with the counting of your bins.’)
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